

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



AS

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : A61K</p>	<p>A2</p>	<p>(11) International Publication Number: WO 00/06085 (43) International Publication Date: 10 February 2000 (10.02.00)</p>
<p>(21) International Application Number: PCT/US99/17118 (22) International Filing Date: 28 July 1999 (28.07.99) (30) Priority Data: 60/094,424 28 July 1998 (28.07.98) US 60/094,414 28 July 1998 (28.07.98) US (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): NEEB, Michael, J. [US/US]; 414 Bill Smith Boulevard, King of Prussia, PA 19406 (US). BONDINELL, William, E. [US/US]; 1512 Franklin Lane, Wayne, PA 19087 (US). KU, Thomas, W. [US/US]; 1413 Southwind Way, Dresher, PA 19025 (US). (74) Agents: STEIN-FERNANDEZ, Nora et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).</p>		<p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: COMPOUNDS AND METHODS (57) Abstract This invention relates to substituted heteroanilide compounds which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOUNDS AND METHODS

FIELD OF THE INVENTION

5 This invention relates to substituted heteroanilide compounds which are modulators, agonists or antagonists, of the CC chemokine receptor CC-CCR5 now designated as CCR5 (*Nature Medicine* 1996, 2, 1174-8). In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5.

BACKGROUND OF THE INVENTION

10 T cells are not only key regulators of the immune response to infectious agents but are believed critical for the initiation and maintenance of the inflammatory reaction in a variety of chronic diseases. Increased numbers or enhanced activation state of T cells, especially CD4+ T cells, have been demonstrated in the synovium of individuals with rheumatoid arthritis (M.J. Elliott and R. N. Maini, *Int. Arch. Allergy Immunol.* 104: 112-1125, 1994), in the bronchial
15 mucosa of asthmatics (C.J. Corrigan and A.B. Kay, *Immunol. Today* 13:501-506, 1992), in the lesions of multiple sclerosis (R. Martin and H. F. McFarland, *Crit. Rev. Clin. Lab. Sci.* 32: 121-182, 1995), in psoriatic lesions (J.L. Jones, J. Berth-Jone, A. Fletcher and P.E. Hutchinson, *J. Pathol.* 174: 77-82, 1994) and in the fatty streaks of
20 atherosclerosis (R. Ross, *Annu. Rev. Physiol.* 57: 791-804, 1995).

T cells, as well as other inflammatory cells, will migrate into tissues in response to the production of a variety of chemotactic factors. Among these factors are a superfamily of 8-12 kDa proteins known as the chemokines. These proteins share structural features such as the presence of 3-4 conserved cysteine residues.
25 RANTES, which stands for Regulated upon Activation Normal T cell Expressed and Secreted, is an 8 kDa protein member of CC branch of the chemokine family. These proteins recruit and activate immune and inflammatory cells through an interaction with G-protein coupled receptors. The CC branch is defined by the absence of an intervening amino acid residue between the first two cysteine residues and members
30 of this family predominately elicit the migration of mononuclear cells, eosinophils and basophils (M. Baggiolini, B. Dewald, and B. Moser, *Adv. Immunol.* 55: 97-179, 1994; and J.J. Oppenheim, C.O.C. Zachariae, N. Mukaida, and K. Matsushima, *Annu. Rev. Immunol.* 9: 617-648. 1991).

RANTES potently produces chemotaxis of T cells, basophils, eosinophils,
35 monocytes and mast cells. RANTES was originally identified as gene product induced late after antigen activation of T-cells (T.J. Schall, J. Jongstra, B.J. Dyer, J. Jorgensen, et al., *J. Immunol.* 141:1018-1025, 1988), however, RANTES has been shown to be synthesized and secreted by a diverse group of cells that include

epithelial and endothelial cells (C. Stellato, L.A. Beck, G.A. Gorgone, D. Proud, et al., J. Immunol. 155: 410-418, 1995; and A. Marfaing-Koka, O. Devergne, G. Gorgone, A. Portier, et al., J. Immunol. 154: 1870-1878, 1994), synovial fibroblasts (P. Rathanaswami, M. Hachicha, M. Sadick, T.J. Schall, et al., J. Biol. Chem. 268: 5834-5839, 1993) and dermal fibroblasts (M. Sticherling, M. Kupper, F. Koltowitz, E. Bornscheuer, et al., J. Invest. Dermatol. 105: 585-591, 1995), mesangial cells (G. Wolf, S. Aberle, F. Thaiss, et al., Kidney Int. 44: 795-804, 1994) and platelets (Y. Koameyoshi, A. Dorschner, A.I. Mallet, E. Christophers, et al., J. Exp. Med. 176: 587-592, 1992). In these cells RANTES mRNA is rapidly upregulated in response to IL-1 or TNF α . Although RANTES mRNA is not usually detected in normal tissues (J.M. Pattison, P.J. Nelson, and A.M. Krensky, Clin. Immunother. 4: 1-8, 1995), increased mRNA or protein has been found in diseases characterized by a mononuclear infiltrate. For example, RANTES mRNA was visualized using *in situ* hybridization in renal allografts undergoing rejection (J.M. Pattison, P.J. Nelson, and A.M. Krensky, Clin. Immunother. 4: 1-8, 1995; and K.C. Nadeau, H. Azuma and N.I. Tilney, Proc. Natl. Acad. USA 92: 8729-8733, 1995) in the skin of atopic dermatitis patients after exposure to antigen (S. Ying, L. Taborda-Barata, Q. Meng, M. Humbert, et al., J. Exp. Med. 181: 2153-2159, 1995), and in endothelial cells of coronary arteries undergoing accelerated atherosclerosis after cardiac transplant (J.M. Pattison, P.J. Nelson, and A.M. Krensky, Clin. Immunother. 4: 1-8, 1995). Further, increased immunoreactive protein for RANTES has been detected in bronchoalveolar lavage fluid (R. Alam, J. York, M. Boyers, et al., Am. J. Resp. Crit. Care Med. 149: A951, 1994) and sputum from asthmatic individuals (C.M. Gelder, P.S. Thomas, D.H. Yates, I.M. Adcock, et al., Thorax 50: 1033-1037, 1995).

Several receptors have been identified that bind RANTES. In particular, CCR5, when expressed in either HEK 293 cells or CHO cells, binds RANTES. This receptor is expressed in T-cells and in monocytes and macrophages, immune/inflammatory cells which are important in the maintenance of a chronic inflammatory reaction. Pharmacological characterization of CCR5 indicates similarities to the RANTES binding site observed on isolated T cells. Therefore, antagonism of RANTES' action on CCR5, as well as antagonism of other natural modulators of CCR5, should inhibit the recruitment and activation of T cells and macrophages into inflammatory lesions and provide a novel therapeutic approach for the treatment of atopic and autoimmune disorders.

Since T cells express CCR5, selective receptor modulators of CCR5, particularly antagonists, are likely to provide beneficial effects in diseases including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis and other fibrotic diseases,

atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, preferably humans. Furthermore, since CD8+ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.

Surprisingly, it has now been discovered that this class of non-peptide compounds, in particular substituted heteroanilide compounds of this invention, function as CCR5 receptor modulators, and therefore, have utility in the treatment and prevention of disease states mediated by CCR5 receptor mechanisms.

SUMMARY OF THE INVENTION


In one aspect, the present invention is to novel compounds of formula (I), or pharmaceutically active salts thereof, and their novel use in treating the above-mentioned CCR5-mediated disease states:

Ar-L-E

Formula I

20

in which Ar represents a group of Formula (i) or (ii):



25 wherein:

the basic nitrogen in moiety E may be optionally quaternized with C₁₋₆alkyl or is optionally present as the N-oxide;

P¹ and P² are independently phenyl, fused bicyclic aryl, a monocyclic heterocyclic ring of 5- to 7-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic heterocyclic ring of 8 to 11-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur, providing that at least one of P¹ and P² is a heterocyclic group:

P³ is a monocyclic heterocyclic ring of 5- to 7-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic

heterocyclic ring of 8 to 11-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur:

L is a group of formula $-C(=V)-DR^{6'}$ -, $-DR^{7'}-C(=V)-$, $-CH_2NH-$, or $-NHCH_2-$;

5 V is oxygen or sulfur:

D is nitrogen, carbon, or a CH group,

$R^{1'}$, $R^{2'}$, and $R^{4'}$ are independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl, aryl, $(CH_2)_dNR^{8'}R^{9'}$, $(CH_2)_dNR^{8'}COR^{10'}$, $(CH_2)_dNR^{8'}CO_2R^{11'}$, $(CH_2)_dNR^{8'}SO_2R^{12'}$, $(CH_2)_dCONR^{13'}R^{14'}$, hydroxy C_{1-6} alkyl, C_{1-4} alkoxyalkyl (optionally substituted by a C_{1-4} alkoxy or hydroxy group), $(CH_2)_dCO_2C_{1-6}$ alkyl, $(CH_2)_eOC(O)R^{15'}$, $CR^{16'}=NOR^{17'}$, $CNR^{18'}=NOR^{17'}$, $COR^{19'}$, $CONR^{13'}R^{14'}$, $CONR^{13'}(CH_2)_fOC_{1-4}$ alkyl, $CONR^{13'}(CH_2)_dCO_2R^{20'}$, $CONHNR^{21'}R^{22'}$, $CONR^{13'}SO_2R^{23'}$, $CO_2R^{24'}$, cyano, trifluoromethyl, $NR^{8'}R^{9'}$, $NR^{8'}COR^{10'}$, $NR^{25'}CO(CH_2)_dNR^{25'}R^{26'}$, $NR^{25'}CONR^{25'}R^{26'}$, $NR^{8'}CO_2R^{11'}$, $NR^{8'}SO_2R^{12'}$, $N=CNR^{25'}NR^{25'}R^{26'}$, nitro, hydroxy, C_{1-6} alkoxy, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkoxy, $OC(O)NR^{27'}R^{28'}$, $SR^{29'}$, $SOR^{30'}$, $SO_2R^{30'}$, $SO_2NR^{31'}R^{32'}$, halogen, C_{1-6} alkanoyl, $CO_2(CH_2)_dOR^{33'}$, or $R^{1'}$ is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur:

$R^{3'}$ and $R^{5'}$ are independently hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, hydroxy C_{1-6} alkyl, C_{1-6} alkyl OC_{1-6} alkyl, $CONR^{34'}R^{35'}$, $CO_2R^{36'}$, cyano, aryl, trifluoromethyl, $NR^{37'}R^{38'}$, nitro, hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyl, acyloxy, or halogen:

25 $R^{16'}$, $R^{17'}$, $R^{18'}$, $R^{19'}$, $R^{20'}$, $R^{21'}$, $R^{22'}$, $R^{25'}$, $R^{26'}$, $R^{29'}$, $R^{33'}$, $R^{34'}$, $R^{35'}$, $R^{36'}$, $R^{37'}$, and $R^{38'}$ are independently hydrogen or C_{1-6} alkyl:

$R^{6'}$ is hydrogen or C_{1-6} alkyl, providing that D is nitrogen or a CH group;

$R^{7'}$ is hydrogen or C_{1-6} alkyl, providing that D is nitrogen or a CH group;

$R^{8'}$ and $R^{9'}$ are independently hydrogen or C_{1-6} alkyl, or $R^{8'}$ and $R^{9'}$

30 together with the nitrogen to which they are attached, forms a 5- to 6-membered heterocyclic ring, which may optionally be substituted by an oxo group, and, when there are six members, may optionally contain in the ring one oxygen or one sulfur atom;

$R^{10'}$ is hydrogen, C_{1-6} alkyl, or C_{1-4} alkoxyalkyl;

35 $R^{11'}$, $R^{23'}$, and $R^{30'}$ are independently C_{1-6} alkyl;

$R^{12'}$ is C_{1-6} alkyl or phenyl;

$R^{13'}$ and $R^{14'}$ are independently hydrogen or C_{1-6} alkyl, or $R^{13'}$ and $R^{14'}$

together with the nitrogen to which they are attached form a 5- to 6-membered

saturated heterocyclic ring which, when there are 6 ring members, may optionally contain in the ring one oxygen or one sulfur atom:

$R^{15'}$ is C_{1-4} alkyl, optionally substituted by C_{1-6} alkoxy;

$R^{24'}$ is hydrogen or C_{1-6} alkyl optionally substituted with one or two substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, or $NR^{8'}R^{9'}$;

$R^{27'}$ and $R^{28'}$ are independently hydrogen or C_{1-6} alkyl, or $R^{27'}$ and $R^{28'}$ together with the nitrogen to which they are attached form a 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom;

$R^{31'}$ and $R^{32'}$ are independently hydrogen or C_{1-6} alkyl, or $R^{31'}$ and $R^{32'}$ together with the nitrogen to which they are attached form 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or one sulfur atom;

a' and b' are independently 1, 2, or 3;


c' is 0, 1, or 2;

d' is 1, 2, 3, or 4;

e' is 0, 1, 2, or 3;

f' is 1, 2, or 3;

E represents (a):



in which

B is oxygen, $S(O)_c$, $CR^7=CR^8$, or CR^7R^8 , or B is NR^9 ;

R^1 and R^2 are independently hydrogen or C_{1-6} alkyl; alternatively

$B(CR^1R^2)_a$ is $OCR^1R^2CR^1(OH)CR^1R^2$ or $OCR^1R^2CR^1(OCOCH_3)CR^1R^2$;

R^3 and R^4 are independently hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C_{1-6} alkyl, aryl, $CONR^{10}R^{11}$, $NR^{10}R^{11}$, hydroxy, $OCOR^{12}$, $NHCOC_{0-6}$ alkyl where alkyl is optionally substituted by OH, $NHCOCF_3$, $NHSO_2R^{13}$, and $NHCO_2R^{14}$;

R^5 is hydrogen, C_{1-6} alkyl, aryl, CN, $CONR^{15}R^{16}$, CO_2R^{17} , trifluoromethyl, $NHCO_2R^{18}$, hydroxy, C_{1-6} alkoxy, benzyloxy, $OCH_2CO_2C_{1-6}$ alkyl, OCF_3 , $S(O)_dR^{19}$, $SO_2NR^{20}R^{21}$ or halogen;

R^6 is hydrogen, C_{1-6} alkyl, aryl, trifluoromethyl, hydroxy, C_{1-6} alkoxy or halogen, or R^6 taken together with $R^{6'}$ forms a group D where D is $(CR^{22}R^{23})_e$ or D is $(CR^{22}R^{23})_f-G$ where G is oxygen, sulfur or $CR^{22}=CR^{23}$, $CR^{22}=N$, $=CR^{22}O$, $=CR^{22}S$, or $=CR^{22}-NR^{23}$;

5 $R^7, R^8, R^{10}, R^{11}, R^{12}, R^{15}, R^{16}, R^{17}, R^{20}, R^{21}, R^{22}$, and R^{23} are independently hydrogen or C_{1-6} alkyl;

R^9 is hydrogen, C_{1-6} alkyl, or phenyl C_{1-6} alkyl;

R^{13}, R^{14}, R^{18} , and R^{19} are independently C_{1-6} alkyl;

a is 1, 2, 3, or 4;


10 b is 1 or 2;

c and d are independently 0, 1 or 2;

e is 2, 3 or 4;

f is 0, 1, 2 or 3;

alternatively, E represents (b):



15

(b);

$R^{24}, R^{25}, R^{26}, R^{27}, R^{28}, R^{29}, R^{31}$, and R^{32} are independently hydrogen or C_{1-6} alkyl;

R^{30} is hydrogen, C_{1-6} alkyl, or C_{3-7} cycloalkyl;

20 R^{33} is hydrogen, C_{1-6} alkyl, trifluoromethyl, hydroxy, or halogen, or R^{33} and $R^{6'}$ together form a group -K- where K is $(CR^{34}R^{35})_i$ or K is $(CR^{34}R^{35})_j-M$ and M is oxygen, sulfur, $CR^{34}=CR^{35}$, $CR^{34}=N$, or $N=N$;

J is oxygen, $CR^{36}R^{37}$, or NR^{38} , or J is a group $S(O)_k$

$R^{34}, R^{35}, R^{36}, R^{37}$, and R^{38} are independently hydrogen or C_{1-6} alkyl;

g is 1, 2 or 3;


25 h is 1, 2 or 3;

i is 2, 3, or 4;

j is 0, 1, 2, or 3;

k is 0, 1 or 2;

alternatively, E represents (c):




30

(c);


in which:

Q is oxygen, $S(O)_n$, $CR^{44}=CR^{45}$, $CR^{44}R^{45}$, or Q is NR^{46} ;

R³⁹ and R⁴⁰ are independently hydrogen or C₁₋₆alkyl:
 R⁴¹ is a group of formula (d):



5 or R⁴¹ is a group of formula (e):



R⁴² is hydrogen, C₁₋₆alkyl, aryl, CN, CONR⁴⁸R⁴⁹, CO₂R⁵⁰, trifluoromethyl, NHCO₂R⁵¹, hydroxy, C₁₋₆alkoxy, benzyloxy, OCH₂CO₂C₁₋₆alkyl, OCF₃, S(O)₂R⁵², SO₂NR⁵³R⁵⁴, or halogen;

10 R⁴³ is hydrogen or R⁴³ together with R^{6'} forms a group R where R is CR⁵⁵=CR⁵⁶, CR⁵⁵=CR⁵⁶CR⁵⁵R⁵⁶, or (CR⁵⁵R⁵⁶)_t;

R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁸, R⁴⁹, R⁵⁰, R⁵³, R⁵⁴, R⁵⁵, and R⁵⁶ are independently hydrogen or C₁₋₆alkyl;

R⁴⁷ is hydrogen, C₁₋₆alkyl, or C₃₋₇ cycloalkyl;

15 R⁵¹ and R⁵² are independently C₁₋₆alkyl:

l is 0, 1, 2, or 3;

m is 1 or 2;

n is 0, 1, or 2


o, p, and q are independently integers having the value 1, 2, or 3;

20 r is 0, 1, 2, or 3;

s is 0, 1, or 2;

t is 2 or 3;

alternatively, E represents (f):



25 R⁵⁷ and R⁵⁸ are independently hydrogen or C₁₋₆alkyl;


R⁵⁹ and R⁶⁰ are independently hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an

additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C₁₋₆alkyl, aryl, CONR⁶¹R⁶², NR⁶¹R⁶², hydroxy, OCOR⁶³, NHCOC₀₋₆alkyl where alkyl is optionally substituted by OH, NHCOCF₃, NHSO₂R⁶⁴, and NHCO₂R⁶⁵;

- 5 T is -(CR⁶⁶R⁶⁷)_v- or -O(CR⁶⁶R⁶⁷)_w-;
 W is oxygen, S(O)_x, NR⁶⁸, or W is CR⁶⁹=CR⁷⁰ or CR⁶⁹R⁷⁰;
 R⁶¹, R⁶², R⁶³, R⁶⁶, R⁶⁷, R⁶⁸, R⁶⁹, and R⁷⁰ are independently hydrogen or C₁₋₆alkyl;

- R⁶⁴ and R⁶⁵ are independently C₁₋₆alkyl;
 10 u is 1 to 4;
 v is 2 or 3;
 w is 1, 2, or 3;
 x is 0, 1 or 2;

alternatively, E represents a group (g):



- R⁷¹ is an optionally substituted 5 to 7-membered saturated or partially saturated heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur or R⁷¹ is an optionally substituted 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from
 20 oxygen, nitrogen or sulfur;


R⁷² is hydrogen, C₁₋₆alkyl, aryl, CN, CONR⁷⁴R⁷⁵, CO₂R⁷⁶, trifluoromethyl, NHCO₂R⁷⁷, hydroxy, C₁₋₆alkoxy, benzyloxy, OCH₂CO₂C₁₋₆alkyl, OCF₃, S(O)₂R⁷⁸, SO₂NR⁷⁹R⁸⁰, or halogen:

- R⁷³ is hydrogen, C₁₋₆alkyl, hydroxy, C₁₋₆alkoxy or halogen, or R⁷³ and
 25 R⁶, taken together from a group -X- where X is (CR⁸¹R⁸²)_{aa} or X is (CR⁸¹R⁸²)_{ab}-
 Y and Y is oxygen, sulfur or CR⁸¹=CR⁸²;

R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁹, R⁸⁰, R⁸¹, and R⁸² are independently hydrogen or C₁₋₆alkyl;

- R⁷⁷ and R⁷⁸ are independently C₁₋₆alkyl;
 30 y is 1 or 2;
 z is 0, 1, or 2;
 aa is 2, 3 or 4;
 ab is 0, 1, 2 or 3;

alternatively, E represents group (h):



R⁸³ and R⁸⁴ are independently hydrogen or C₁₋₆alkyl;

R⁸⁵ and R⁸⁶ are independently hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C₁₋₆alkyl, aryl, CONR⁸⁸R⁸⁹, NR⁹⁰R⁹¹, hydroxy, OCOR⁹², NHCOC₀₋₆alkyl where alkyl is optionally substituted by OH, NHCOCF₃, NHSO₂R⁹³, and NHCO₂R⁹⁴;

R⁸⁷ is hydrogen or C₁₋₆alkyl, C₁₋₆alkoxy, or halogen, or R⁸⁷ together with R^{6'} forms a group -AA- where AA is (CR⁹⁵R⁹⁶)_{ad} or AA is (CR⁹⁵=CR⁹⁶)_{ae}-AB and AB is oxygen, sulfur, CR⁹⁵=CR⁹⁶, CR⁹⁵=N, CR⁹⁵NR⁹⁶ or N=N;

Z is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur;

R⁸⁸, R⁸⁹, R⁹⁰, R⁹¹, R⁹², R⁹⁵, and R⁹⁶ are independently hydrogen or C₁₋₆alkyl;


R⁹³ and R⁹⁴ are independently C₁₋₆alkyl;

ac is 0 to 4;

ad is 1, 2 or 3;

ae is 0, 1 or 2;

alternatively, E represents group (i):



R⁹⁷ and R⁹⁸ are independently hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C₁₋₆alkyl, aryl, CONR¹⁰²R¹⁰³, NR¹⁰⁴R¹⁰⁵, hydroxy, OCOR¹⁰⁶, NHCOC₀₋₆alkyl where alkyl is optionally substituted by OH, NHCOCF₃, NHSO₂R¹⁰⁷, and NHCO₂R¹⁰⁸;

R⁹⁹ and R¹⁰⁰ are independently hydrogen or C₁₋₆alkyl;

R¹⁰¹ is hydrogen or C₁₋₆alkyl or R¹⁰¹ and R^{6'} together form a group - AD- where AD is (CR¹⁰⁹R¹¹⁰)_{ai} or AD is (CR¹⁰⁹R¹¹⁰)_{aj}-AE and AE is oxygen, sulfur or CR¹⁰⁹=CR¹¹⁰;

- 5 AC is oxygen, CR¹¹¹R¹¹² or NR¹¹³ or AC is a group S(O)_{ak};
 R¹⁰², R¹⁰³, R¹⁰⁴, R¹⁰⁵, R¹⁰⁶, R¹⁰⁹, R¹¹⁰, R¹¹¹, R¹¹², and R¹¹³ are
 independently hydrogen or C₁₋₆alkyl;
 R¹⁰⁷ and R¹⁰⁸ are independently C₁₋₆alkyl;
 af is 0, 1, 2, 3, or 4;
 ag is 1, 2, or 3;
 10 ah is 1, 2, 3 or 4;
 ai is 2, 3 or 4;
 aj is 0, 1, 2, or 3; and
 ak is 0, 1 or 2.

15 DETAILED DESCRIPTION OF THE INVENTION

- It has now been discovered that substituted anilides of formula (I) are CCR5
 receptor modulators. It has also now been discovered that selective inhibition of
 CCR5 receptor mechanisms by treatment with the receptor modulators of formula
 (I), or a pharmaceutically acceptable salt thereof, represents a novel therapeutic and
 20 preventative approach to the treatment of a variety of disease states, including, but
 not limited to, COPD, asthma and atopic disorders (for example, atopic dermatitis
 and allergies), rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic
 disease, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory
 bowel disease, all in mammals, preferably humans ("CCR5-mediated diseases").
 25 Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor
 modulators may be useful in the treatment of HIV infection.

- The term "alkyl" is used herein at all occurrences to mean a straight or branched
 chain radical of 1 to 6 carbon atoms, unless the chain length is limited thereto, including,
 but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,
 30 and the like.

The terms "cycloalkyl" and "cyclic alkyl" are used herein at all occurrences to mean
 cyclic radicals, preferably comprising 3 to 7 carbon atoms which may be mono- or bicyclo-
 fused ring systems which may additionally include unsaturation, including, but not limited
 to, cyclopropyl, cyclopentyl, cyclohexyl, and the like.

- 35 The terms "halo" or "halogen" are used interchangeably herein at all occurrences to
 mean radicals derived from the elements chlorine, fluorine, iodine and bromine.

The term "heterocyclic ring" is used herein at all occurrences to mean a saturated or
 partially saturated 5-, 6-, or 7-membered ring system (unless the cyclic ring system is

otherwise limited) in which the ring system contains one to 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which ring system may be optionally substituted with C₁-6alkyl or C₃-7cycloalkyl. Examples of such rings include, but are not limited to, piperidine, tetrahydropyridine, and piperazine. When the heterocyclic ring is fused to a phenyl group, the term "heterocyclic ring", together with the phenyl ring to which it is fused, forms a ring which includes, but is not limited to, dihydro-1,4-benzoxazine and 1,2,3,4-tetrahydroquinoline, which may be optionally substituted by C₁-6alkyl or oxo.

The term "6,6 or 6,5 bicyclic ring" means a 6,6 or 6,5-bicyclic ring system containing a nitrogen atom and optionally a further heteroatom selected from nitrogen, oxygen, or sulfur, which ring system may be optionally substituted with C₁-6alkyl. Examples of such ring systems include, but are not limited to, tropane, isoquinuclidine and granatane rings.

The term "CCR5 mediated disease state" is used herein at all occurrences to mean any disease state which is mediated (or modulated) by CCR5.

The term "monocyclic heterocyclic ring" is used herein at all occurrences to mean a single aromatic ring of 5 to 7 members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur represented by P¹ and/or P² include thienyl, furyl, pyrrolyl, and pyridyl.

The term "fused bicyclic heterocyclic ring" is used herein at all occurrences to mean a fused bicyclic aromatic ring system of 8 to 11-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur include indole, benzofuran, benzothiophene, quinoline, and isoquinoline rings.

Suitably, pharmaceutically acceptable salts of formula (I) include, but are not limited to, salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate, or salts with an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, palmitate, salicylate, and stearate.

The compounds of the invention can exist in unsolvated as well as solvated forms, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol, and the like, are equivalent to the unsolvated forms for purposes of this invention.

The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. The stereocenters may be of any combination of R and S configuration, for example, (R,R), (R,S), (S,S) or (S,R). All of these compounds are within the scope of the present invention.

For the compounds of formula (I) various embodiments are as follows. It will be understood that the basic nitrogen in moiety E may be optionally quaternized with C₁-6alkyl or is optionally present as the N-oxide.

wherein:

P¹ and P² are suitably independently phenyl, fused bicyclic aryl, a monocyclic heterocyclic ring of 5- to 7-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic heterocyclic ring of 8 to 11-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur, providing that at least one of P¹ and P² is a heterocyclic group. Preferably, P¹ and P² are phenyl, pyrrolyl, thienyl, thiazolyl, 1,2,3-triazolyl, pyridyl, and benzodioxanyl, providing that at least one of P¹ or P² is a heterocyclic group. More preferably, P¹ and P² are phenyl, thienyl, and benzodioxanyl, providing that at least one of P¹ and P² is a heterocyclic group.

P³ is suitably a monocyclic heterocyclic ring of 5- to 7-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic heterocyclic ring of 8 to 11-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur. P³ is preferably thienyl, pyridyl, indolyl, benzofuranyl, benzothienyl, and benzopyranyl. More preferably, P³ is indolyl, benzofuranyl, and benzopyranyl.

When R^{1'} is a 5- to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen, or sulfur, suitable heterocyclic rings include aromatic groups such as thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, and dioxanyl. Saturated and partially saturated rings are also within the scope of the invention, in particular rings including an oxo or thioxo moiety such as lactams and thiolactams. Suitably, the heterocyclic ring can be linked to the remainder of the molecule via a carbon atom, or, when present, a nitrogen atom. Suitable substituents for these rings include one to two of R^{3'}.

L is a suitably group of formula -C(=V)-DR^{6'}-, -DR^{7'}-C(=V)-, -CH₂NH-, or -NHCH₂-. L is preferably -C(=V)-DR^{6'}-.

V is suitably oxygen or sulfur. V is preferably oxygen.

D is suitably nitrogen, carbon, or a CH group. D is preferably nitrogen.

R^{1'}, R^{2'}, and R^{4'} are suitably independently hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, aryl, (CH₂)_dNR^{8'}R^{9'}, (CH₂)_dNR^{8'}COR^{10'}, (CH₂)_dNR^{8'}CO₂R^{11'}, (CH₂)_dNR^{8'}SO₂R^{12'}, (CH₂)_dCONR^{13'}R^{14'}, hydroxyC₁₋₆alkyl, C₁₋₄alkoxyalkyl (optionally substituted by a C₁₋₄alkoxy or hydroxy group), (CH₂)_dCO₂C₁₋₆alkyl, (CH₂)_eOC(O)R^{15'}, CR^{16'}=NOR^{17'}, CNR^{18'}=NOR^{17'}, COR^{19'}, CONR^{13'}R^{14'}, CONR^{13'}(CH₂)_fOC₁₋₄alkyl, CONR^{13'}(CH₂)_dCO₂R^{20'}, CONHN^{21'}R^{22'}, CONR^{13'}SO₂R^{23'}, CO₂R^{24'}, cyano, trifluoromethyl, NR^{8'}R^{9'}, NR^{8'}COR^{10'}, NR^{25'}CO(CH₂)_dNR^{25'}R^{26'}, NR^{25'}CONR^{25'}R^{26'}, NR^{8'}CO₂R^{11'}, NR^{8'}SO₂R^{12'},

N=CNR^{25'}NR^{25'}R^{26'}, nitro, hydroxy, C₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, OC(O)NR^{27'}R^{28'}, SR^{29'}, SOR^{30'}, SO₂R^{30'}, SO₂NR^{31'}R^{32'}, halogen, C₁₋₆alkanoyl, CO₂(CH₂)_dOR^{33'}, or R^{1'} is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur. Preferably, R^{1'}, R^{2'}, and R^{4'} are hydrogen, C₁₋₆alkyl, trifluoromethyl, or halogen.

R^{3'} and R^{5'} are suitably independently hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, hydroxyC₁₋₆alkyl, C₁₋₆alkylOC₁₋₆alkyl, CONR^{34'}R^{35'}, CO₂R^{36'}, cyano, aryl, trifluoromethyl, NR^{37'}R^{38'}, nitro, hydroxy, C₁₋₆alkoxy, C₁₋₆alkanoyl, acyloxy, or halogen. Preferably, R^{3'} and R^{5'} are hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, or halogen.

R^{16'}, R^{17'}, R^{18'}, R^{19'}, R^{20'}, R^{21'}, R^{22'}, R^{25'}, R^{26'}, R^{29'}, R^{33'}, R^{34'}, R^{35'}, R^{36'}, R^{37'}, and R^{38'} are suitably independently hydrogen or C₁₋₆alkyl.

R^{6'} is suitably hydrogen or C₁₋₆alkyl, providing that D is nitrogen or a CH group. Preferably, R^{6'} is hydrogen.

R^{7'} is suitably hydrogen or C₁₋₆alkyl, providing that D is nitrogen or a CH group.

R^{8'} and R^{9'} are suitably independently hydrogen or C₁₋₆alkyl, or R^{8'} and R^{9'} together with the nitrogen to which they are attached, forms a 5- to 6-membered heterocyclic ring, which may optionally be substituted by an oxo group, and, when there are six members, may optionally contain in the ring one oxygen or one sulfur atom.

R^{10'} is hydrogen, C₁₋₆alkyl, or C₁₋₄alkoxyalkyl.

R^{11'}, R^{23'}, and R^{30'} are independently C₁₋₆alkyl.

R^{12'} is C₁₋₆alkyl or phenyl.

R^{13'} and R^{14'} are independently hydrogen or C₁₋₆alkyl, or R^{13'} and R^{14'} together with the nitrogen to which they are attached form a 5- to 6-membered saturated heterocyclic ring which, when there are 6 ring members, may optionally contain in the ring one oxygen or one sulfur atom.

R^{15'} is C¹⁻⁴alkyl, optionally substituted by C₁₋₆alkoxy.

R^{24'} is hydrogen or C₁₋₆alkyl optionally substituted with one or two substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, hydroxy, or NR^{8'}R^{9'}.

R^{27'} and R^{28'} are independently hydrogen or C₁₋₆alkyl, or R^{27'} and R^{28'} together with the nitrogen to which they are attached form a 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom.

R^{31'} and R^{32'} are independently hydrogen or C₁₋₆alkyl, or R^{31'} and R^{33'} together with the nitrogen to which they are attached form 5- to 6-membered

heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom.

a' and b' are independently 1, 2, or 3.


c' is 0, 1, or 2.

5 d' is 1, 2, 3, or 4.

e' is 0, 1, 2, or 3.

f' is 1, 2, or 3.

E suitably represents (a):



10

(a);

in which

B is suitably oxygen, S(O)_c, CR⁷=CR⁸, or CR⁷R⁸, or B is NR⁹. B is preferably CR⁷R⁸, or oxygen. More preferably, B is CH₂ or oxygen.

R¹ and R² are suitably independently hydrogen or C₁₋₆alkyl; alternatively
 15 B(CR¹R²)_a is OCR¹R²CR¹(OH)CR¹R² or OCR¹R²CR¹(OCOCH₃)CR¹R².
 Preferably, R¹ and R² are hydrogen.

R³ and R⁴ are suitably independently hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an
 20 additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C₁₋₆alkyl, aryl, CONR¹⁰R¹¹, NR¹⁰R¹¹, hydroxy, OCOR¹², NHCOC₀₋₆alkyl where alkyl is optionally substituted by OH, NHCOCF₃, NHSO₂R¹³, and NHCO₂R¹⁴. Preferably R³ and R⁴ are both C₁₋₆alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-
 25 membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur. More preferably, R³ and R⁴ are C₃₋₆alkyl, or together with the nitrogen to which they are attached form a 6-membered ring, optionally substituted with one or more of C₁₋₆alkyl, N-acetamido, or hydroxy. Most preferably, R³ and R⁴ are isopropyl or R³ is isopropyl and R⁴ is tert-butyl, or
 30 together with the nitrogen to which they are attached are 1-(2,2,6,6-tetramethylpiperidinyl), 1-(4-acetamido-2,2,6,6-tetramethylpiperidinyl), 1-(4-hydroxy-2,2,6,6-tetramethylpiperidinyl), or 1-(4-hydroxy-2,2,4,6,6-pentamethylpiperidinyl).

Preferably, B-(CR¹R²)_a-NR³R⁴ is ortho to R⁵, meta to L, and para to R⁶,
 35 and R⁵ is para to L.

R^5 is suitably hydrogen, C_{1-6} alkyl, aryl, CN, $CONR^{15}R^{16}$, CO_2R^{17} , trifluoromethyl, $NHCO_2R^{18}$, hydroxy, C_{1-6} alkoxy, benzyloxy, $OCH_2CO_2C_{1-6}$ alkyl, OCF_3 , $S(O)_dR^{19}$, $SO_2NR^{20}R^{21}$, or halogen. R^5 is preferably C_{1-6} alkoxy, SC_{1-6} alkyl or halogen; more preferably methoxy, methylthio or iodo, most

5 preferably methoxy. When R^5 is methoxy, it is preferably para to L.

R^6 is suitably hydrogen, C_{1-6} alkyl, aryl, trifluoromethyl, hydroxy, C_{1-6} alkoxy, or halogen, or R^6 taken together with $R^{6'}$ forms a group D where D is $(CR^{22}R^{23})_e$ or D is $(CR^{22}R^{23})_f-G$ where G is oxygen, sulfur, or $CR^{22}=CR^{23}$, $CR^{22}=N$, $=CR^{22}O$, $=CR^{22}S$, or $=CR^{22}-NR^{23}$. Preferably, R^6 is hydrogen.

10 R^7 , R^8 , R^{10} , R^{11} , R^{15} , R^{16} , R^{17} , R^{20} , R^{21} , R^{22} , and R^{23} are independently hydrogen or C_{1-6} alkyl.

R^9 is hydrogen, C_{1-6} alkyl, or phenyl C_{1-6} alkyl.

R^{12} , R^{13} , R^{14} , R^{18} , and R^{19} are independently C_{1-6} alkyl.

a is suitably 1, 2, 3, or 4. Preferably, a is 2 or 3, more preferably, a is 2 or 3
15 when B is oxygen and a is 2 when B is CH_2 , most preferably, a is 2 when B is oxygen.


b is suitably 1 or 2. Preferably, b is 1.

c and d are suitably independently 0, 1, or 2.

e is suitably 2, 3, or 4.

20 f is suitably 0, 1, 2, or 3.

alternatively, E suitably represents (b):



R^{24} , R^{25} , R^{26} , R^{27} , R^{28} , R^{29} , R^{31} , and R^{32} are suitably independently hydrogen or C_{1-6} alkyl. R^{24} , R^{25} , R^{26} , R^{27} , R^{28} , R^{29} , R^{31} , and R^{32} are
25 preferably hydrogen.

R^{30} is suitably hydrogen, C_{1-6} alkyl, or C_{3-7} cycloalkyl. Preferably, R^{30} is C_{1-6} alkyl, more preferably, R^{30} is C_{3-6} alkyl, most preferably, R^{30} is isopropyl.

R^{33} is suitably hydrogen, C_{1-6} alkyl, trifluoromethyl, hydroxy or halogen, or
30 R^{33} and $R^{6'}$ together form a group -K- where K is $(CR^{34}R^{35})_i$ or K is $(CR^{34}R^{35})_j$ -M and M is oxygen, sulfur, $CR^{34}=CR^{35}$, $CR^{34}=N$, or $N=N$. Preferably, R^{33} is hydrogen.

J is suitably oxygen, $CR^{36}R^{37}$, or NR^{38} , or J is a group $S(O)_k$. Preferably, J is oxygen. Preferably, J is para to L.

R^{34} , R^{35} , R^{36} , R^{37} , R^{38} are suitably independently hydrogen or C_{1-6} alkyl.

g is suitably 1, 2, or 3. Preferably, g is 2 or 3, more preferably 2.

h is suitably 1, 2, or 3. Preferably, h is 1.


i is suitably 2, 3, or 4.

j is suitably 0, 1, 2, or 3.

5 k is suitably 0, 1 or 2.

A preferred subgenus of the compounds of formula (I) are compounds of formula (Ia) and formula (Ib) in which $R^{1'}$, $R^{2'}$, $R^{3'}$, $R^{4'}$, $R^{5'}$, P^1 , P^2 , P^3 , a' , b' , c' , L , R^{24} , R^{25} , R^{26} , R^{27} , R^{28} , R^{29} , R^{30} , R^{31} , R^{32} , R^{33} , J , g , and h are defined as above:

10



Formula (Ia)

Formula (Ib)

15 Among the preferred compounds of the invention are the following compounds:

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-5-(4-pyridinyl)-2-furancarboxamide;

20 N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-5-(4-pyridyl)-thiophene-2-carboxamide;

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-5-(4-pyridinyl)-3-furancarboxamide;

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(3-thienyl)-benzamide dioxalate;

25 4-Methoxy-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-5-(4-pyridinyl)-3-thiophenecarboxamide;

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(2-thienyl)-3-methylbenzamide oxalate;

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-phenyl-2-thiazolyl)benzamide;

30 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-(1-pyrrolyl)pyridin-3-carboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-thiophenecarboxamide;

- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide;
- 6-Chloro-N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide;
- 5 5-Bromo-N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide;
- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-thiophenecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(3-pyridinyl)benzamide;
- 10 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-pyridinyl)benzamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thiazolyl)-benzamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-phenyl-3-pyridinecarboxamide;
- 15 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(4-pyridinyl)benzamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-phenyl-2-pyridinecarboxamide;
- 20 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2-thienyl)benzamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thienyl)benzamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-phenyl-2-thiophenecarboxamide;
- 25 N-[1'-Isopropyl-spiro[benzofuran-3(2H),4'-piperidin]-5-yl]-2-(2,3-dihydro-1,4-benzodioxan-2-yl)-4-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
- 30 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;
- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;
- 35 N-[3-[2-(Dimethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

(+)-N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

(-)-N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

5 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(3-bromo-2-thienyl)-4-thiazolecarboxamide;

10 N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(3-bromo-2-thienyl)-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-(3-bromo-2-thienyl)-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-methyl-5-thiazolecarboxamide;

15 N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-methyl-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-methyl-5-thiazolecarboxamide;

20 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-phenyl-4-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-phenyl-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-phenyl-4-thiazolecarboxamide;

25 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-phenyl-5-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-phenyl-5-thiazolecarboxamide;

30 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-4-methyl-2-(4-chlorophenyl)-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(4-chlorophenyl)-5-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(4-chlorophenyl)-5-thiazolecarboxamide;

35 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;

- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;
- 5 N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;
- 10 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dichlorophenyl)-4-thiazolecarboxamide;
- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dichlorophenyl)-4-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-(2,3-dichlorophenyl)-4-thiazolecarboxamide;
- 15 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;
- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;
- 20 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-pyrazinyl-5-thiazolecarboxamide;
- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;
- 25 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-(4-chlorophenyl)-5-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-chlorobenzo[b]thiophene-2-carboxamide;
- N-[3-[3-[Bis(1-methylethyl)amino]propyl]-4-methoxyphenyl]-3-chlorobenzo[b]thiophene-2-carboxamide;
- 30 N-[3-[3-[Bis(1-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-chlorobenzo[b]thiophene-2-carboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide;
- 35 N-[3-[3-[Bis(1-methylethyl)amino]propyl]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide;
- N-[3-[3-[Bis(1-methylethyl)amino]propoxy]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-1H-indole-2-carboxamide; and

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-2-benzofurancarboxamide.

5 Among the more preferred compounds of the invention are the following compounds:

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thienyl)benzamide;

10 N-[3-[2-(Diisopropylamino)ethoxy]-4-methoxyphenyl]-5-phenyl-2-thiophenecarboxamide;

N-[1'-Isopropyl-spiro[benzofuran-3(2H),4'-piperidin]-5-yl]-2-(2,3-dihydro-1,4-benzodioxan-2-yl)-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

15 (+)-N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

(-)-N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

20 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide;

N-[3-[3-[Bis(1-methylethyl)amino]propoxy]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-1H-indole-2-carboxamide; and

25 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-2-benzofurancarboxamide.

Among the compounds specifically excluded from the scope of this invention are the following compounds:

30 N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide;

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-pyridinyl)-benzamide dioxalate;

N-[4-Methoxy-3-(1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide;

35 N-[4-Methoxy-3-(4-ethyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide oxalate;

N-[4-Methoxy-3-(4-benzyl-1-piperazinyl)phenyl]-3-methyl-4-(4-pyridinyl)benzamide oxalate;

- N-[4-(1-Methyl-3-piperidinyl)methoxyphenyl]-3-methyl-4-(4-pyridinyl)benzamide;
- N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-5-(2-pyridinyl)-2-thiophenecarboxamide oxalate;
- 5 N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-methoxyphenyl)-2-thiazolyl)benzamide;
- N-[3-[2-(Dimethylamino)ethoxy]-4-methoxyphenyl]-3-methyl-4-(4-pyridinyl)benzamide;
- N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-5-(3-pyridinyl)-3-thiazolecarboxamide;
- 10 1'-Methyl-5-{4-[2-methyl-6-(2-oxopyrrolidin-1-yl)pyrid-3-yl]}benzoyl}-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine] hydrochloride;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-nitro-2-furancarboxamide;
- 15 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-furancarboxamide;
- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-5-nitro-2-furancarboxamide;
- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-furancarboxamide;
- 20 N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide;
- 6-Chloro-N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide;
- 5-Bromo-N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide;
- 25 N-[3-[2-(Dimethylamino)ethoxy]-4-methoxyphenyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
- N-[3-[2-(Dimethylamino)ethoxy]-4-methoxyphenyl]-2-thiophenecarboxamide;
- N-[3-[2-(Dimethylamino)ethoxy]-4-methoxyphenyl]-5-nitro-2-furancarboxamide;
- 30 N-[3-[2-(Dimethylamino)ethoxy]-4-methoxyphenyl]-2-furancarboxamide;
- 6-Chloro-N-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide;
- 5-Bromo-N-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide.
- 35 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;

- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(4-methyl-1,2,3-thiadiazol-5-yl)-4-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-4-methyl-2-phenyl-5-thiazolecarboxamide;
- 5 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-(2-pyridinyl)-5-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-(2,3-dichlorophenyl)-4-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-(2-pyrazinyl)thiazole-5-carboxamide;
- 10 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-(3-pyridinyl)-4-thiazolecarboxamide;
- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-(3-pyridinyl)-4-thiazolecarboxamide;
- 15 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-4-methyl-2-(3-pyridinyl)-4-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(4-methyl-1,2,3-thiadiazol-5-yl)-4-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-(4-methyl-1,2,3-thiadiazol-5-yl)-4-thiazolecarboxamide;
- 20 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(4-chlorophenyl)-4-methyl-5-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-(4-chlorophenyl)-4-methyl-5-thiazolecarboxamide;
- 25 N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(4-pyridinyl)-4-thiazolecarboxamide;
- N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(4-pyridinyl)-4-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-(4-pyridinyl)-4-thiazolecarboxamide;
- 30 N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-(3-pyridinyl)-5-thiazolecarboxamide;
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-(4-pyridinyl)-5-thiazolecarboxamide;
- 35 N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-(4-pyridinyl)-5-thiazolecarboxamide; and
- N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-4-methyl-2-(4-pyridinyl)-5-thiazolecarboxamide.

A subgenus of formula (I) wherein E is (a); B is meta to L; B-(CR¹R²)_a-NR³R is -(CH₂)₃N(CH₃)(C₀₋₃alkyl); R⁵ is hydrogen, methyl, hydroxy, C₁₋₃alkoxy, halogen; R⁶ is hydrogen, hydroxy, methoxy; L is CONH, NHCO or NHCH₂; Ar is (i); R^{3'} is hydrogen; P¹ is phenyl and P² is attached in the 4-position; P² is 2-furyl, 2-thienyl, imidazol-4-yl, 1,2,4-triazol-3-yl, 2-, 3-, or 4-pyridinyl; R^{1'} and R^{2'} are independently hydrogen, methyl, hydroxymethyl, 1-(hydroxy)ethyl, formyl, acetyl, carboxamido, carboxy, carbomethoxy; R^{3'} is hydrogen, has been described in GB 2276163, published 21 September 1994, and GB 2276164, published 21 September 1994; as 5-HT antagonists.

10 A compound of formula (I) wherein: E is (a); B is meta to L; B-(CR¹R²)_a-NR³R is -O-(CH₂)₂N(CH₃)₂; R⁵ is iodo; R⁶ is hydrogen; L is CONH; Ar is (ii); R^{4'} and R^{5'} are hydrogen; P³ is 4-quinolinyl has been described in international patent application number WO 98/50343, published 12 November 1998, as a 5-HT receptor antagonist.

15 A subgenus of formula (I) wherein: E is (b); R²⁴, R²⁵, R²⁶⁻²⁹, R³¹⁻³² are hydrogen; R³⁰ is hydrogen, methyl; J is para to L; J is oxygen; g is 2; h is 1, R³³ and R^{6'} together are -(CH₂)₂-; Ar is (i); P² is phenyl and P¹ is attached at the 4-position; P¹ is 3-pyridinyl; R^{1'} is 2-oxo-1-pyrrolidinyl, 1,3,4-oxadiazol-2-yl; R^{2'} is methyl; R^{3'} is hydrogen has been described in international patent application number WO 97/17351, published 15 May 1997 as 5-HT receptor antagonists.

20 A subgenus of formula (I) wherein: E is (c); Q is ortho to L; Q-(CR³⁹R⁴⁰)_l-R⁴¹ is (CH₂)₂-2-piperidinyl; R⁴⁷ is methyl; R⁴², R⁴³, R^{3'}, and R^{4'} are hydrogen; L is CONH; P³ is 3-furyl, 2-thienyl, 2-, 3-, and 4-pyridinyl, have been described in United States Patent 3,931,195, published January 6, 1976, and United States Patent 4,000,143, published December 28, 1976, and reported to have antiserotonin activity.

A subgenus of formula (I) wherein: E is (g); R⁷¹ is meta to L; R⁷¹ is (C₀₋₂alkyl-1-piperazine); R⁷² is hydrogen, methyl, hydroxy, C₁₋₄alkoxy, halogen; R⁷³ is hydrogen, hydroxy, methoxy, or fluoro; R^{1'}, and R^{2'} are hydrogen, methyl, acetyl; R^{3'} is hydrogen, methyl, nitro, hydroxy, methoxy, or fluoro; R^{4'} and R^{5'} are independently hydrogen, methoxy, bromo; L is CONH or NHCO; Ar is (i) or (ii); P¹ is phenyl and P² is attached at the 4-position, or 2,5-furyl, 3,5-furyl, 2,5-thienyl, 3,5-thienyl, 3,6-pyridinyl, 1,4-naphthalenyl, 1,5-naphthalenyl; P² is 2-furyl, 3-thienyl, 2-, 3-, or 4-pyridinyl, 5-pyrimidinyl, 1,2,4-oxadiazol-3-yl, pyrazol-1-yl, 1,2,4-triazol-1-yl, imidazol-1-yl; P³ is 2-, and 3-furyl, 2-thienyl, 3-thienyl, 2,5-thienyl, 3-pyridinyl, 4-quinolinyl; has been described in in EP 533267, published 24 March 1993, GB 2273930, published 6 July 1994; GB 2276164, published 21 September 1994; international patent application number WO 95/04729, published 16 February

1995; international patent application number WO 95/06644, published 9 March 1995; international patent application number WO 98/47885, published 29 October 1998, as 5-HT receptor antagonists.

A compound of formula (I) wherein: E is (g); R⁷¹ is meta to L; R⁷¹ is (methyl-1-piperazine); R⁷² is 4-methoxy; R⁷³ is hydrogen; L is CONR^{6'}; R⁷³ and R^{6'} are -(CH₂)₂-; Ar is (ii); R^{4'} and R^{5'} are independently methoxy or bromo; P³ is 3-thienyl; has been described in international patent application number WO 95/06637, published 9 March 1995 as a 5-HT receptor antagonist.

A subgenus of formula (I) wherein: the basic nitrogen in moiety E may be optionally quaternized with C₁₋₆alkyl or is optionally present as the N-oxide. E is (b). J is CH₂. g is 1, 2, or 3. h is 1, 2, or 3. R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³¹, and R³² are hydrogen. R³⁰ is hydrogen or C₁₋₆alkyl. R³³ is hydrogen, C₁₋₆alkyl, trifluoromethyl, or halogen. L is CONR^{8'}, or NR^{9'}CO. R^{8'} and R^{9'} are independently hydrogen or C₁₋₆alkyl. P¹ is phenyl. P² is heteroaryl, wherein heteroaryl is selected from the group consisting of benzimidazolyl, benzofuranyl, benzooxazolyl, furanyl, imidazolyl, indolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolyl, quinolyl, thiadiazolyl, thiazolyl, thienyl or triazolyl. R^{1*} is hydrogen. R^{2*} is hydrogen or 1, 2, or 3 of hydroxy, cyano, halogen, trifluoromethyl, NR^{8*}COR^{10*}, NR^{8*}CO₂R^{11*}, NR^{25*}CONHR^{25*}, NHS(O)₀₋₂R^{12*}, CONR^{13*}R^{14*}, COC₁₋₅alkyl, CO₂R^{24*}, C₁₋₆alkoxy, SR^{29*}, SOR^{30*}, SO₂R^{30*}, or phenyl. R^{3*} is hydrogen or 1 or 2 of hydroxy, cyano, halogen, trifluoromethyl, CONR^{34*}R^{35*}, COC₁₋₅alkyl, CO₂R^{36*}, C₁₋₆alkoxy, or phenyl. R^{8*}, R^{13*}, R^{14*}, R^{25*}, R^{29*}, R^{34*}, R^{35*}, and R^{36*} are independently hydrogen or C₁₋₆alkyl. R^{10*} is hydrogen C₁₋₆alkyl, or C₁₋₄alkoxyC₁₋₆alkyl. R^{11*} and R^{30*} are independently C₁₋₆alkyl. R^{12*} is C₁₋₆alkyl or phenyl. R^{24*} is hydrogen or C₁₋₆alkyl optionally substituted with one or two of hydroxy or C₁₋₆alkoxy, has been described in WO 98/25604, published 18 June 1998, as chemokine receptor modulators.

A subgenus of formula (I) wherein: the basic nitrogen in moiety E may be optionally quaternized with C₁₋₆alkyl or is optionally present as the N-oxide. E is (b). J is CH₂. g is 1, 2, or 3. h is 1, 2, or 3. R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³¹, and R³² are hydrogen. R³⁰ is hydrogen or C₁₋₆alkyl. R³³ is hydrogen, C₁₋₆alkyl, trifluoromethyl, or halogen. L is CH₂NH. P¹ and P³ are heteroaryl, wherein heteroaryl is selected from the group consisting of benzimidazolyl, benzofuranyl, benzooxazolyl, furanyl, imidazolyl, indolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolyl, quinolyl, thiadiazolyl, thiazolyl, thienyl or triazolyl. P² is phenyl. R^{1*} and R^{2*} are hydrogen. R^{3*} and R^{5*} are hydrogen or 1 or 2 of hydroxy, cyano, halogen, trifluoromethyl, CONR^{34*}R^{35*}, COC₁₋₅alkyl, CO₂R^{36*}, C₁₋₆alkoxy, or phenyl. R^{4*} is hydrogen or 1 of hydroxy, cyano, halogen, trifluoromethyl, NR^{8*}COR^{10*}, NR^{8*}CO₂R^{11*}, NR^{25*}CONHR^{25*}, NHS(O)₀₋₂R^{12*}, CONR^{13*}R^{14*}, COC₁₋₅alkyl, CO₂R^{24*}, C₁₋

- 6alkoxy, SR^{29*}, SOR^{30*}, SO₂R^{30*}, or phenyl. R^{8*}, R^{13*}, R^{14*}, R^{25*}, R^{29*}, R^{34*}, R^{35*}, and R^{36*} are independently hydrogen or C₁₋₆alkyl. R^{10*} is hydrogen C₁₋₆alkyl, or C₁₋₄alkoxyC₁₋₆alkyl. R^{11*} and R^{30*} are independently C₁₋₆alkyl. R^{12*} is C₁₋₆alkyl or phenyl. R^{24*} is hydrogen or C₁₋₆alkyl optionally substituted with one or two of hydroxy or C₁₋₆alkoxy, has been described in WO 98/25605, published 18 June 1998, as chemokine receptor modulators.

Formulation of Pharmaceutical Compositions

- The pharmaceutically effective compounds of this invention (and the pharmaceutically acceptable salts thereof) are administered in conventional dosage forms prepared by combining a compound of this invention ("active ingredient") in an amount sufficient to treat COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, and HIV infection, ("CCR5-mediated disease states") with standard pharmaceutical carriers or diluents according to conventional procedures well known in the art. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.

- The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.

- A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1000 mg. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.

- The active ingredient may also be administered topically to a mammal in need of treatment or prophylaxis of CCR5 mediated disease states. The amount of active ingredient required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the disease state being treated and the mammal undergoing treatment, and is ultimately at the discretion of the physician. A suitable dose of an active ingredient is 1.5 mg to 500 mg for topical

administration, the most preferred dosage being 1 mg to 100 mg, for example 5 to 25 mg administered two or three times daily.

By topical administration is meant non-systemic administration and includes the application of the active ingredient externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream. By systemic administration is meant oral, intravenous, intraperitoneal and intramuscular administration.

While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e.g. from 1% to 2% by weight of the formulation although it may comprise as much as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1% to 1% w/w of the formulation.

The topical formulations of the present invention, both for veterinary and for human medical use, comprise an active ingredient together with one or more acceptable carrier(s) therefor and optionally any other therapeutic ingredient(s). The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.

Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous or alcoholic solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include

an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

5 Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or
10 suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene
15 glycol. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as siliceous silicas, and other ingredients such as lanolin, may also be included.

The active ingredient may also be administered by inhalation. By "inhalation" is meant intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques. The daily dosage amount of the active ingredient
20 administered by inhalation is from about 0.1 mg to about 100 mg per day, preferably about 1 mg to about 10 mg per day.

In one aspect, this invention relates to a method of treating COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis and other fibrotic diseases, atherosclerosis, psoriasis,
25 autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, and HIV infection, all in mammals, preferably humans, which comprises administering to such mammal an effective amount of a CCR5 receptor modulator, in particular, a compound of this invention.

By the term "treating" is meant either prophylactic or therapeutic therapy.
30 Such compound can be administered to such mammal in a conventional dosage form prepared by combining the compound of this invention with a conventional pharmaceutically acceptable carrier or diluent according to known techniques. It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active
35 ingredient with which it is to be combined, the route of administration and other well-known variables. The compound is administered to a mammal in need of treatment for COPD, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, psoriasis, autoimmune diseases such

as multiple sclerosis, inflammatory bowel disease, and HIV infection. in an amount sufficient to decrease symptoms associated with these disease states. The route of administration may be oral or parenteral.

5 The term parenteral as used herein includes intravenous, intramuscular, subcutaneous, intra-rectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. The daily parenteral dosage regimen will preferably be from about 30 mg to about 300 mg per day of active ingredient. The daily oral dosage regimen will preferably be from about 100 mg to about 2000 mg per day of active ingredient.

10 It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of this invention will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular mammal being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of
15 skill in the art that the optimal course of treatment, i.e., the number of doses of the compound given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.


Methods of Preparation

20 Compounds of formula (I) are prepared by condensing suitably substituted heteroaryl carboxylic acids and suitably substituted anilines, which are commercially available or synthesized by methods known to the art from commercially available starting materials, using methods known to the art. For example, suitably substituted heteroaryl carboxylic acids, are treated with a suitable reagent, such as thionyl
25 chloride, at a suitable temperature, such as at reflux, to afford heteroaryl carbonyl chlorides, and the acid chlorides are condensed with suitably substituted anilines in the presence of a suitable base, such as diisopropylethylamine, in a suitable solvent, such as dichloromethane, to give compounds of formula (I). Many additional methods for converting a carboxylic acid to an amide are known, and can be found
30 in standard reference books, such as "Compendium of Organic Synthetic Methods", Vol. I-VI (published by Wiley-Interscience).

Specifically, compounds of this invention were prepared according to the methods described herein and by the methods of: United States Patent 3,931,195, published January 6, 1976, United States Patent 4,000,143, published December 28,
35 1976, EP 533267, published 24 March 1993; GB 2273930, published 6 July 1994; GB 2276163, published 21 September 1994; GB 2276164, published 21 September 1994; international patent application number WO 95/04729, published 16 February 1995; international patent application number WO 95/06637, published 9 March

1995; international patent application number WO 95/06644, published 9 March 1995; international patent application number WO 97/17351, published 15 May 1997; international patent application number WO 98/47885, published 29 October 1998; and international patent application number WO 98/50343, published 12
5 November 1998.

Compounds of this invention are also prepared using solid-phase chemistry as described herein and using the general method described in international patent application WO 99/01127, published 14 January 1999. As describe in Scheme I, appropriately substituted (2-alkylamino)ethoxy-anilines I-2, such as 3-[2-
10 (diisopropylamino)ethoxy]-4-methoxyaniline, synthesized from commercially available 2-methoxy-5-nitrophenol, I-1, according to the procedures described in WO 99/01127, are reacted with 4-formyl-3,5-dimethoxyphenol-Merrifield resin 1-3 (Boojamra, et al., *J. Org. Chem.* 1995, 60, 5742) and a suitable reducing agent, such as sodium triacetoxyborohydride, in a suitable solvent, such as dimethylformamide
15 containing 1% acetic acid, to afford I-4. The resin-bound aniline I-4 is condensed with an appropriately substituted heteroaryl carboxylic acid I-5, which are commercially available or synthesized by methods known to the art, using a suitable activating agent, such as N-bromosuccinimide and triphenylphosphine, in a suitable solvent, such as dichloromethane, dimethylformamide and pyridine, to afford I-6.
20 For example, 1-4 is treated with a ten-fold excess of an equimolar mixture of a 3-heteroaryl carboxylic acid, triphenylphosphine and N-bromosuccinimide, in a suitable solvent, such as dichloromethane, after which a ten-fold excess of a suitable base, such as pyridine, is added, and the mixture is gently agitated for a suitable time. for example, forty-eight hours, to afford the resin-bound amide 1-6.
25 Optionally, dimethylformamide may be added to the resulting mixture to increase the solubility of the heteroaryl carboxylic acid. Treatment of I-6 with a suitable acid and solvent, such as trifluoroacetic:dichloromethane:water (50:48:2) gives I-7 which are compounds of this invention.

Scheme I:

- (a) $\text{Cl}(\text{CH}_2)_2\text{NR}^3\text{R}^4$, K_2CO_3 , CH_3COCH_3 ; (b) H_2 , 5% Pd/C , MeOH ; (c) Merrifield resin bound aldehyde (3), $\text{NaBH}(\text{OAc})_3$, 1% HOAc/DMF ; (d) 3-aryl- or heteroarylcarboxylic acid, N-bromosuccinimide, Ph_3P , pyridine, CH_2Cl_2 ; (e) TFA , CH_2Cl_2 , H_2O

The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. In the Examples, mass spectra were performed upon a VG Zab mass spectrometer using fast atom bombardment, unless otherwise indicated.

EXAMPLES**Preparation 1**

Preparation of 4-(3-Pyridinyl)benzoyl Chloride

a) 4-(3-pyridinyl)benzoic acid

A mixture of 4-carboxybenzeneboronic acid (0.5 g, 2.9 mmol), 3-bromopyridine (0.46 g, 2.9 mmol), sodium carbonate (1.37 g), and tetrakis(triphenylphosphine)palladium(0) (0.1 g) in 50% aqueous 1,2-dimethoxyethane (70 mL) was heated to reflux for 16 h, cooled, acidified, and extracted with dichloromethane. The organic phase was dried and concentrated *in vacuo* to yield the title compound, which was used without further purification.

b) 4-(3-pyridinyl)benzoyl chloride

The compound of Preparation 1(a) (0.2 g, 1 mmol) was refluxed in thionyl chloride (5 mL) for 30 min, the mixture was concentrated *in vacuo*, treated with dichloromethane, and concentrated *in vacuo* to afford the title compound.

Preparation 2Preparation of 4-(2-Pyridinyl)benzoyl Chloride

a) ethyl 4-(2-pyridinyl)benzoate

4-(Ethoxycarbonyl)phenylzinc iodide in tetrahydrofuran (0.5M, 2 mL, 1 mmol) was added to a solution of 2-bromopyridine (0.16 g, 1 mmol) and tetrakis(triphenylphosphine)palladium(0) (63 mg, 0.05 mmol) in tetrahydrofuran (5 mL) and stirred at RT for 3 h. The reaction was quenched with saturated ammonium chloride and extracted three times with ethyl acetate. The combined organic phase was dried (MgSO₄), concentrated *in vacuo*, and the residue chromatographed (silica gel, 10% ethyl acetate/hexane) to give the title compound as a yellow solid (0.15 g).

b) 4-(2-pyridinyl)benzoic acid

The compound of Preparation 2(a) (0.15 g, 0.66 mmol) was dissolved in ethanol (5 mL), treated with concentrated hydrochloric acid (1 mL) and water (2 mL), heated to 80°C for 16 h, and then heated to reflux for 3 h. The mixture was concentrated *in vacuo* to afford the title compound.

c) 4-(2-pyridinyl)benzoyl chloride

Following the procedure of Preparation 1(b), except substituting the compound of Preparation 2(b) for the compound of Preparation 1(a), afforded the title compound.

Preparation 3Preparation of 4-(2-Thiazolyl)benzoyl Chloride

a) ethyl 4-(2-thiazolyl)benzoate

Following the general procedure of Preparation 2(a), except substituting 2-thiazolezinc bromide for 4-(ethoxycarbonyl)phenylzinc, and ethyl 4-iodobenzoate for 2-bromopyridine, gave the title compound (0.2 g).

b) 4-(2-thiazolyl)benzoic acid

The compound of Preparation 3(a) (0.2 g, 0.86 mmol) was dissolved in methanol (5 mL), treated with concentrated hydrochloric acid (2 mL) and water (8 mL), heated to 80°C for 16 h. and then heated to reflux for 3 h, concentrated *in vacuo*, and azeotropered with dichloromethane to give the title compound.

5 c) 4-(2-thiazolyl)benzoyl chloride

Following the procedure of Preparation 1(b), except substituting the compound of Preparation 3(b) for the compound of Preparation 1(a), afforded the title compound.

Preparation 4

10 **Preparation of 6-Phenyl-3-pyridinecarbonyl Chloride**

a) 5-methyl-2-(phenyl)pyridine

Following the procedure of Preparation 2(a), except substituting 5-methyl-2-pyridinylzinc bromide for 4-(ethoxycarbonyl)phenylzinc iodide and iodobenzene for 2-bromopyridine, afforded the title compound.

15 b) 6-phenyl-3-pyridinecarboxylic acid

A mixture of the compound of Preparation 4(a) (0.4 g, 2.4 mmol) and water (25 mL) was heated to 90°C and treated with a solution of potassium permanganate (1.58 g, 10 mmol) in a mixture of water (25 mL) and pyridine (25 mL) added slowly. After the purple color disappeared, additional potassium permanganate (1.58 g) was added and the mixture stirred for 5 h. The hot mixture was filtered, the filter cake was washed with water, and the filtrate was concentrated *in vacuo* to give a white solid, which was dissolved in water (50 mL) and acidified with 3N hydrochloric acid until no additional precipitate formed. The precipitate was filtered and air-dried to give the title compound. MS(ES) m/e 199.7 [M+H]⁺.

25 c) 6-phenyl-3-pyridinecarbonyl chloride

Following the procedure of Preparation 1(b), except substituting the compound of Preparation 4(b) for the compound of Preparation 1(a), gave the title compound.

Preparation 5

30 **Preparation of 4-(4-Pyridinyl)benzoyl Chloride**

a) 4-(4-pyridinyl)benzoic acid

4-Bromopyridine hydrochloride (0.4 g, 2 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.5 g, 2 mmol), and tetrakis(triphenylphosphine)palladium(0) (50 mg, 0.04 mmol) in dimethylformamide (15 mL) was treated with 2M potassium carbonate (2 mL) and the mixture was heated to 80°C for 16 h. The mixture was concentrated *in vacuo* and the residue was diluted with water to afford a solid which was filtered to afford the title compound (0.26 g).

b) 4-(4-pyridinyl)benzoyl chloride

Using the procedure of Preparation 1(b), except substituting the compound of Preparation 5(a) for the compound of Preparation 1(a), afforded the title compound.

Preparation 65 **Preparation of 5-Phenyl-2-pyridinecarbonyl Chloride**

a) 2-methyl-5-(phenyl)pyridine

A solution of 3-(phenyl)pyridine (1.55 g, 10 mmol) in tetrahydrofuran (10 ml) was stirred at -78°C and treated with methyllithium (1.4 M, 7.5 mL, 10 mmol) in ether. The resulting yellow solution was stirred for 1 h, allowed to warm to 0°C, 10 stirred 1 h, quenched with saturated ammonium chloride, and extracted with ether. The combined organic phase was washed with water and with brine, dried (MgSO₄), and concentrated *in vacuo*. The residue was chromatographed (silica gel, 25% ethyl acetate/hexane) to give the title compound (0.36 g).

b) 5-phenyl-2-pyridinylcarbonyl chloride

15 Following the general procedure of Preparation 4(b)-(c), except substituting the compound of Preparation 6(a) for the compound of Preparation 4(a), gave the title compound.

Preparation 7**Preparation of 5-phenyl-2-thiophenecarboxylic Acid**

20 Following the procedure of Preparation 1(a), except substituting phenylboronic acid for 4-carboxybenzeneboronic acid and 5-bromo-2-thiophenecarboxylic acid for 3-bromopyridine, afforded the title compound.

Preparation 8**Preparation of N-[1'-(1-Methylethyl)spiro[benzofuran-3(2H),4'-piperidin]-5-amine**

25 a) 5- and 7-nitro-spiro[benzofuran-3(2H),4'-piperidine]

A solution of 1'-methyl-5- and 7-nitro-spiro[benzofuran-3(2H),4'-piperidine] (WO 96/11934) (3 g, 12 mmol) and diisopropylethylamine (2.5 g, 19 mmol) in 1,2-dichloroethane (80 mL) was treated with 1-chloroethyl chloroformate (2.3 g, 16 mmol) at RT, stirred for 1 h, and heated to reflux for 20 min. The mixture was 30 cooled, concentrated *in vacuo*, and the residue was dissolved in methanol and heated to reflux for 2 h, concentrated *in vacuo*, and the residue was partitioned between dichloromethane (250 mL) and 5% sodium bicarbonate (50 mL). The organic phase was washed with 5% sodium bicarbonate (50 mL) and the combined aqueous phase was extracted with dichloromethane (2 X 50 mL). The combined organic phase was 35 dried (Na₂SO₄) and concentrated to afford the title compound (2.65 g).

b) 1'-(tert-butoxycarbonyl)-5-nitro-spiro[benzofuran-3(2H),4'-piperidine]

A solution of the compound of Preparation 8(a) (2.65 g, 1.13 mmol) in tetrahydrofuran (300 mL) was treated with di-tert-butyl dicarbonate (2.6 g, 12 mmol)

and stirred at RT for 16 h. The mixture was concentrated *in vacuo* and the residue was crystallized from methanol to afford the title compound (2.1 g).

c) 5-nitro-spiro[benzofuran-3(2H),4'-piperidine]

A solution of the compound of Preparation 8(b) (2.1 g, 6.3 mmol) in dichloromethane (50 mL) and trifluoroacetic acid (10 mL) was kept at RT for 5 h, concentrated *in vacuo*, and the residue was partitioned between dichloromethane (300 mL) and 5% sodium bicarbonate. The organic phase was washed with 5% sodium bicarbonate and the combined aqueous washes were extracted with dichloromethane. The combined organic phase was dried (Na₂SO₄) and concentrated *in vacuo* to give the title compound (1.45 g): MS(ES) m/e 235.1 [+H]⁺.

d) 5-nitro-1'-(1-methylethyl)spiro[benzofuran-3(2H),4'-piperidine]

A mixture of the compound of Preparation 8(c) (1.45 g, 6.2 mmol), powdered potassium carbonate (0.86 g, 6.2 mmol) and dimethylformamide (50 mL) containing 2-iodopropane (1.1 g, 6.4 mmol) was stirred and heated to 50°C for 4 h, treated with 2-iodopropane (0.17 g, 1 mmol) at 50°C for 90 min, and treated with 2-iodopropane (0.1 g, 1 mmol) at 50°C for 2 h. The mixture was concentrated *in vacuo* and the residue was partitioned between ethyl acetate (200 mL) and water (20 mL). The organic phase was washed, dried (MgSO₄), concentrated *in vacuo*, and the residue was chromatographed (silica gel, 5% methanol/dichloromethane) to give the title compound (0.85 g).

e) N-[1'-(1-methylethyl)spiro[benzofuran-3(2H),4'-piperidin]-5-amine

A solution of the compound of Preparation 8(d) (0.78 g, 2.8 mmol) in methanol (250 mL) containing 10% palladium-on-carbon (0.375 g) was shaken in a hydrogen atmosphere (40 psi) for 40 min, filtered, and concentrated *in vacuo* to afford the title compound (0.6 g).

Preparation 9

Preparation of 4-methyl-2-pyrazinyl-5-thiazolecarbonyl chloride

Following the procedure of Preparation 1(b), except substituting 4-methyl-2-pyrazinyl-5-thiazolecarboxylic acid for the compound of Preparation 1(a) afforded the title compound.

Example 1

Preparation of N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thienyl)benzamide

A solution of 2-thienylzinc bromide in tetrahydrofuran (0.5M, 5 mL, 2.5 mmol) was added to a solution of N-[3-[2-(diisopropylamino)ethoxy]-4-methoxyphenyl]-4-iodobenzamide (WO 99/01127) (0.5g, 1 mmol) in tetrahydrofuran (5 mL) containing tetrakis(triphenylphosphine)palladium(0) (80 mg, 0.06 mmol), and the mixture was stirred at RT for 16 h. The reaction was quenched

with saturated ammonium chloride and extracted with ether and dichloromethane. The organic phase was dried (MgSO_4), concentrated *in vacuo*, and chromatographed (silica gel, 5% methanol/dichloromethane) to afford the title compound (0.1 g). MS(ES) m/e 452.8 $[\text{M}+\text{H}]^+$.

5

Example 2**Preparation of N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(3-pyridinyl)benzamide**

The compound of Preparation 1(b) was dissolved in dichloromethane (5 mL) and treated with 3-[2-(diisopropylamino)ethoxy]-4-methoxyaniline (WO 95/15954) (0.27 g, 1 mmol) followed by diisopropylethylamine (0.14 g, 1 mmol). The mixture was stirred at RT for 16 h, diluted with dichloromethane, extracted twice with 5% sodium carbonate and with water, dried (MgSO_4), concentrated *in vacuo*, and the residue chromatographed (silica gel, 5% methanol/dichloromethane) to give the title compound (20 mg). MS(ES) m/e 448.0 $[\text{M}+\text{H}]^+$.

15

Examples 3-7

Preparation of N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-(1-pyrrolyl)-3-pyridinecarboxamide; N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-pyridinyl)benzamide; N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thiazolyl)benzamide; N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-phenyl-3-pyridinecarboxamide; and N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(4-pyridinyl)benzamide

Following the procedure of Example 2, except substituting the compounds of Preparation 2(c), Preparation 3(c), Preparation 4(c), and Preparation 5(b) for the compound of Preparation 1(b), gave the title compounds:

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-(1-pyrrolyl)-3-pyridinecarboxamide: MS(ES) m/e 437.2 $[\text{M}+\text{H}]^+$;

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-pyridinyl)benzamide: MS(ES) m/e 448.0 $[\text{M}+\text{H}]^+$;

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thiazolyl)benzamide: MS(ES) m/e 454.1 $[\text{M}+\text{H}]^+$;

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-phenyl-3-pyridinecarboxamide: MS(ES) m/e 448.0 $[\text{M}+\text{H}]^+$; and

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(4-pyridinyl)benzamide: MS(ES) m/e 448.2 $[\text{M}+\text{H}]^+$.

35

Example 8**Preparation of N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-phenyl-2-pyridinecarboxamide**

A solution of the compound of Preparation 6(b) (0.4 g, 2 mmol), 3-[2-(diisopropylamino)]-4-methoxyaniline (WO 95/15954) (0.53 g, 2 mmol), and BOP reagent (0.88 g, 2 mmol) in acetonitrile (30 mL) was treated with triethylamine (0.6 g, 6 mmol), and the mixture was stirred for 16 h. The mixture was diluted with
5 dichloromethane, and extracted with 5% sodium carbonate and with water. The organic phase was dried (MgSO₄), concentrated *in vacuo*, and the residue was chromatographed (silica gel, 5% methanol/dichloromethane) to afford the title compound (0.24 g). MS(ES) m/e 448.2 [M+H]⁺.

Example 9

10 Preparation of N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2-thienyl)benzamide

Following the procedure of Example 1, except substituting N-[3-[2-(diisopropylamino)ethoxy]-4-methoxyphenyl]-3-iodobenzamide (WO 99/01127) for
15 N-[3-[2-(diisopropylamino)ethoxy]-4-methoxyphenyl]-4-iodobenzamide, gave the title compound. MS(ES) m/e 496.7 [M+H]⁺.

Example 10

Preparation of N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-phenyl-2-thiophenecarboxamide

Following the procedure of Example 8, except substituting the compound of
20 Preparation 7 for the compound of Preparation 6(c), gave the title compound. MS(ES) m/e 453.0 [M+H]⁺.

Example 11

Preparation of N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-thiophenecarboxamide

25 a) 3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyaniline]/(4-formyl-3,5-dimethoxyphenoxy)-Merrifield resin adduct

A mixture of 4-formyl-3,5-dimethoxyphenoxy-Merrifield resin (Boojamra et al., *J. Org. Chem.* 1995, 60, 5742), 3-[2-(diisopropylamino)ethoxy]-4-methoxyaniline (WO 95/15954), and sodium triacetoxymethylborohydride in
30 dimethylformamide containing 1% acetic acid was shaken to afford the title adduct.

b) N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-thiophenecarboxamide/(4-formyl-3,5-dimethoxyphenoxy)-Merrifield resin adduct

The resin of Example 11(a) in dimethylformamide was treated with pyridine (10 equivalents) and with a mixture of 10 equivalents each of 2-thiophenecarboxylic
35 acid, N-bromosuccinimide and triphenylphosphine. The resin was washed to afford the title adduct.

c) N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-thiophenecarboxamide

The resin of Example 11(b) was stirred in a mixture of trifluoroacetic acid:dichloromethane:water (50:48:2), filtered, and the filtrate concentrated *in vacuo* to afford the title compound. MS(ES) m/e 377.0 [M+H]⁺.

Examples 12-14

- 5 Following the procedure of Example 11(b)-11(c), except substituting 3-pyridinecarboxylic acid, 6-chloro-3-pyridinecarboxylic acid, and 5-bromo-3-pyridinecarboxylic acid for 2-thiophenecarboxylic acid, afforded the title compounds:

10 N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide: MS(ES) m/e 372.0 [M+H]⁺;

6-chloro- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide: MS(ES) m/e 406.0 [M+H]⁺; and

5-bromo- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide: MS(ES) m/e 450.0 [M+H]⁺.

Example 15

15 Preparation of N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2-thiophenecarboxamide

- Following the procedure of Example 11, except substituting 3-(2-diethylamino)ethoxy-4-methoxyaniline (WO 96/23769) for 3-[2-(diisopropylamino)ethoxy]-4-methoxyaniline, afforded the title compound. MS(ES) m/e 349.0 [M+H]⁺.

Example 16

Preparation of N-[1'-Isopropyl-spiro[benzofuran-3(2H).4'-piperidin]-5-yl]-2-(2,3-dihydro-1,4-benzodioxan-2-yl)-4-thiazolecarboxamide

- 25 Following the procedure of Example 8, except substituting 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxylic acid for the compound of Preparation 6(b) and the compound of Preparation 8(e) for 3-[2-(diisopropylamino)ethoxy]-4-methoxyaniline, gave the title compound). MS(ES) m/e 492.0 [M+H]⁺.

Example 17

- 30 Preparation of N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide

Following the procedure of Example 2, except substituting 2-(1,4-benzodioxan-2-yl)thiazole-4-carbonyl chloride for the compound of Preparation 1(b), gave the title compound. MS(ES) m/e 512.1 [M+H]⁺.

Examples 18-19

- 35 Preparation of (+)-N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide and (-)-N-[3-[2-[Bis(1-

methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide

The compound of Example 17 was resolved by HPLC (Chiralcel OJ, 21.2 X 250 mm, 15 mL/min, 0.1:99.9 diethylamine/methanol, UV detection at 254 nm) to afford the title compounds:

(+)-N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide: MS(ES) m/e 512.0 [M+H]⁺; [[•]]D = +10.4°; and

(-)-N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide: MS(ES) m/e 512.0 [M+H]⁺; [[•]]D = -10.2°.

Example 20

Preparation of N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-pyrazinyl-5-thiazolecarboxamide

Following the procedure of Example 2, except substituting the compound of Preparation 9 for the compound of Preparation 1(b) afforded: the title compound. mp 105-106°C

Examples 21-22

Preparation of N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-1H-indole-2-carboxamide and N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-2-benzofurancarboxamide

Following the procedure of Example 8, except substituting 5-chloro-1H-indole-2-carboxylic acid and 5-chloro-2-benzofurancarboxylic acid for the compound of Preparation 6(b) and purifying the residues obtained by HPLC (ODS-A, 20 X 50 mm, A:acetonitrile B:water-0.1% trifluoroacetic acid, 10-90% during 10 min, UV detection at 254 nm) afforded the title compounds:

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-1H-indole-2-carboxamide: MS(ES) m/e 443.7 [M+H]⁺; and

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-2-benzofurancarboxamide: MS(ES) m/e 445.1 [M+H]⁺.

Example 23

Preparation of N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide

Following the general procedure of Example 11(b)-(c), the resin of Example 11(a) in dichloromethane was treated with 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarbonyl chloride, DMAP, and pyridine. The resin was washed and treated with a mixture of trifluoroacetic acid:dichloromethane:water to afford the title compound. MS(ES) m/e 484.0 [M+H]⁺.

Examples 24-26

Following the procedure of Example 23, except using 3-[2-(diethylamino)ethoxy]-4-methoxyaniline, 3-[2-(dimethylamino)ethoxy]-4-methoxyaniline and 3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyaniline and
5 using 5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxyl chloride and 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarbonyl chloride, afforded the title compounds:

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide: MS(ES) m/e 452.2 [M+H]⁺;

N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide: MS(ES) m/e 424.0 [M+H]⁺; and
10

N-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide: MS(ES) m/e 456.0 [M+H]⁺.

Examples 27-55

Following the procedure of Example 11(a)-(c), except using 3-[2-(diethylamino)ethoxy]-4-methoxyaniline and 3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyaniline and substituting 4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolecarboxylic acid, 2-(3-bromo-2-thienyl)-4-thiazolecarboxylic acid, 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-methyl-5-thiazolecarboxylic acid, 2-phenyl-4-thiazolecarboxylic acid, 4-methyl-2-phenyl-5-thiazolecarboxylic acid, 4-methyl-2-(4-chlorophenyl)-5-thiazolecarboxylic acid, 4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolecarboxylic acid, 2-[2-chloro-4-(trifluoromethyl)phenyl]-4-thiazolecarboxylic acid, 2-(2,3-dichlorophenyl)-4-thiazolecarboxylic acid, 2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxylic acid, and 4-methyl-2-(4-chlorophenyl)-5-thiazolecarboxylic acid for 2-thiophenecarboxylic
20 acid, afforded the title compounds:

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolecarboxamide: MS(ES) m/e 536.2 [M+H]⁺;

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(3-bromo-2-thienyl)-4-thiazolecarboxamide: MS(ES) m/e 538.1 [M+H]⁺;

N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2-(3-bromo-2-thienyl)-4-thiazolecarboxamide: MS(ES) m/e 510.0 [M+H]⁺;

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-2-(3-bromo-2-thienyl)-4-thiazolecarboxamide: MS(ES) m/e 508.1 [M+H]⁺;

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-methyl-5-thiazolecarboxamide: MS(ES) m/e 526.2 [M+H]⁺;

N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-methyl-5-thiazolecarboxamide: MS(ES) m/e 498.2 [M+H]⁺;

- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-methyl-5-thiazolecarboxamide: MS(ES) m/e 496.0 [M+H]⁺;
- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-phenyl-4-thiazolecarboxamide: MS(ES) m/e 454.2 [M+H]⁺;
- 5 N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2-phenyl-4-thiazolecarboxamide: MS(ES) m/e 426.0 [M+H]⁺;
- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-2-phenyl-4-thiazolecarboxamide: MS(ES) m/e 424.0 [M+H]⁺;
- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-phenyl-5-thiazolecarboxamide: MS(ES) m/e 468.2 [M+H]⁺;
- 10 N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-phenyl-5-thiazolecarboxamide: MS(ES) m/e 440.2 [M+H]⁺;
- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-4-methyl-2-(4-chlorophenyl)-5-thiazolecarboxamide: MS(ES) m/e 472.2 [M+H]⁺;
- 15 N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(4-chlorophenyl)-5-thiazolecarboxamide: MS(ES) m/e 488.2 [M+H]⁺;
- N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2-(4-chlorophenyl)-5-thiazolecarboxamide: MS(ES) m/e 460.0 [M+H]⁺;
- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolecarboxamide: MS(ES) m/e 536.2 [M+H]⁺;
- 20 N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolecarboxamide: MS(ES) m/e 508.2 [M+H]⁺;
- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolecarboxamide: MS(ES) m/e 506.2 [M+H]⁺;
- 25 N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]-4-thiazolecarboxamide: MS(ES) m/e 556.2 [M+H]⁺;
- N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]-4-thiazolecarboxamide: MS(ES) m/e 528.0 [M+H]⁺;
- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]-4-thiazolecarboxamide: MS(ES) m/e 526.2 [M+H]⁺;
- 30 N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dichlorophenyl)-4-thiazolecarboxamide: MS(ES) m/e 522.1 [M+H]⁺;
- N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dichlorophenyl)-4-thiazolecarboxamide: MS(ES) m/e 494.1 [M+H]⁺;
- 35 N-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-2-(2,3-dichlorophenyl)-4-thiazolecarboxamide: MS(ES) m/e 492.1 [M+H]⁺;
- N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxamide: MS(ES) m/e 522.2 [M+H]⁺;

N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxamide: MS(ES) m/e 494.2 [M+H]⁺;

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxamide: MS(ES) m/e 492.2 [M+H]⁺;

- 5 N-[3-[2-(diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolecarboxamide: MS(ES) m/e 508.2 [M+H]⁺; and
N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-(4-chlorophenyl)-5-thiazolecarboxamide: MS(ES) m/e 502.2 [M+H]⁺.

Examples 56-60

- 10 Following the procedure of Example 11(a)-(c), except using 3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyaniline, 3-[3-[bis(1-methylethyl)amino]propyl]-4-methoxyaniline and 3-[3-[bis(1-methylethyl)amino]propoxy]-4-methoxyaniline and substituting 3-chloro-benzo[b]thiophene-2-carboxylic acid and 6-chloro-2H-1-benzopyran-3-carboxylic
15 acid for 2-thiophenecarboxylic acid, afforded the title compounds:

N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-chloro-benzo[b]thiophene-2-carboxamide: MS(ES) m/e 461.0 [M+H]⁺;

N-[3-[3-[bis(1-methylethyl)amino]propyl]-4-methoxyphenyl]-3-chloro-benzo[b]thiophene-2-carboxamide: MS(ES) m/e 459.2 [M+H]⁺;

- 20 N-[3-[3-[bis(1-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-chloro-benzo[b]thiophene-2-carboxamide: MS(ES) m/e 475.0 [M+H]⁺;

N-[3-[3-[bis(1-methylethyl)amino]propyl]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide: MS(ES) m/e 457.2 [M+H]⁺; and

- 25 N-[3-[3-[bis(1-methylethyl)amino]propoxy]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide: MS(ES) m/e 473.2 [M+H]⁺.

Example 61

Preparation of N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide

- 30 Following the procedure of Example 8, except substituting 6-chloro-2H-1-benzopyran-3-carboxylic acid for the compound of Example 6(b) afforded the title compound. MS(ES) m/e [M+H]⁺.

Biological Data:

- 35 CCR5 Receptor Binding Assay CHO cell membranes (0.25 x 10⁶ cell equivalents) derived from CHO cells stably transfected with CCR5 were incubated with 0.3 ¹²⁵I-RANTES in a 96 well plate for 45 min at room temperature (final reaction volume 200 ul). The reaction was terminated by filtration and the filters (GF/C) were washed twelve times with a solution of phosphate buffered saline containing 0.1 % bovine serum albumin and 0.05 %

NaN₃. The radioactivity bound to filters was measured by liquid scintillation spectrometry. Non-specific binding was determined in the presence of unlabelled RANTES (10 or 30 nM) and averages 30-50% of total binding.

5 CCR5 Receptor Functional Assay

The cellular functional assay used to assess antagonist activity of compounds was RANTES-induced Ca²⁺ mobilization in RBL 2H3 cells stably expressing the hCCR5 receptor (RBL 2H3 hCCR5). Agonist activity is determined by Ca²⁺ mobilization in the same cells which is inhibitable by a selective CCR5 antagonist. Cells were grown to 80-100% confluency in T-150 flasks and washed with phosphate-buffered saline. Cells were lifted from the flasks by treating with 3 mL of 1 mM EDTA for 3 min at room temperature and diluting to 2 X 10⁶ cells/mL with Krebs Ringer Henseleit buffer (KRH; 118 mM NaCl, 4.6 mM KCl, 25 mM NaHCO₃, 1 mM KH₂PO₄ and 11 mM glucose) containing 5 mM HEPES (pH 7.4), 1 mM CaCl₂, 1 mM MgCl₂ and 0.1% BSA and centrifuged at 200g for 3 min. Cells were resuspended at 2 X 10⁶ cells/mL in the same buffer with 2 μM Fura-2AM, and incubated for 35 min at 37° C. Cells were centrifuged at 200 x g for 3 min and resuspended in the same buffer without Fura-2AM, then incubated for 15 min at 37° C to complete the hydrolysis of intracellular Fura-2AM, and then centrifuged as before. Cells (10⁶ cells/mL) were resuspended in cold KRH with 5 mM HEPES (pH 7.4), 1 mM CaCl₂, 1 mM MgCl₂ and 0.1% gelatin and maintained on ice until assayed. For antagonist studies, aliquots (2 mL) of cells were prewarmed at 37° C for 5 min in 3 mL plastic cuvettes and fluorescence measured in a fluorometer (Johnson Foundation Biomedical Group, Philadelphia, PA, USA) with magnetic stirring and temperature maintained at 37° C. Excitation was set at 340 nm and emission set at 510 nm. Various concentrations of antagonists or vehicle were added and fluorescence monitored for ~15 sec to ensure that there was no change in baseline fluorescence, followed by the addition of 33 nM RANTES. Maximal Ca²⁺ attained after 33 nM RANTES stimulation was calculated as described by Grynkiewicz *et al.*, (1985). The percent of maximal RANTES-induced Ca²⁺ was determined for each concentration of antagonist and the IC₅₀, defined as the concentration of test compound that inhibits 50% of the maximal 33 nM RANTES response, obtained from the concentration-response curves (5-7 concentrations of antagonists).

The compounds of this invention show CCR5 receptor modulator activity having IC₅₀ values in the range of 0.0001 to 100 μM. The full structure/activity relationship has not yet been established for the compounds of this invention. However, given the disclosure herein, one of ordinary skill in the art can utilize the present assays in order to determine which compounds of this invention are modulators of the CCR5 receptor and which bind thereto with an IC₅₀ value in the range of 0.0001 to 100 μM.

All publications, including, but not limited to, patents and patent applications cited in this specification, are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

- 5 The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration it is believed that one skilled in the art can, given the preceding description, utilize the present invention to its fullest extent. Therefore any examples are to be construed as
- 10 merely illustrative and not a limitation on the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.


What is claimed is:

1. A method of treating a CCR5-mediated disease state in mammals which comprises administering to a mammal in need of such treatment, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

Ar-L-E

Formula I

in which Ar represents a group of Formula (i) or (ii):



wherein:

the basic nitrogen in moiety E may be optionally quaternized with C₁-₆alkyl or is optionally present as the N-oxide;

P¹ and P² are independently phenyl, fused bicyclic aryl, a monocyclic heterocyclic ring of 5- to 7-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic heterocyclic ring of 8 to 11-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur, providing that at least one of P¹ and P² is a heterocyclic group;

P³ is a monocyclic heterocyclic ring of 5- to 7-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a fused bicyclic heterocyclic ring of 8 to 11-members containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur;

L is a group of formula -C(=V)-DR^{6'}-, -DR^{7'}-C(=V)-, -CH₂NH-, or -NHCH₂-;

V is oxygen or sulfur;

D is nitrogen, carbon, or a CH group,

R^{1'}, R^{2'}, and R^{4'} are independently hydrogen, C₁-₆alkyl, C₂-₆alkenyl, C₂-₆alkynyl, C₃-₇cycloalkyl, C₃-₇cycloalkenyl, aryl, (CH₂)_dNR^{8'}R^{9'}, (CH₂)_dNR^{8'}COR^{10'}, (CH₂)_dNR^{8'}CO₂R^{11'}, (CH₂)_dNR^{8'}SO₂R^{12'}, (CH₂)_dCONR^{13'}R^{14'}, hydroxyC₁-₆alkyl, C₁-₄alkoxyalkyl (optionally

substituted by a C₁₋₄alkoxy or hydroxy group), (CH₂)_dCO₂C₁₋₆alkyl, (CH₂)_eOC(O)R^{15'}, CR^{16'}=NOR^{17'}, CNR^{18'}=NOR^{17'}, COR^{19'}, CONR^{13'}R^{14'}, CONR^{13'}(CH₂)_fOC₁₋₄alkyl, CONR^{13'}(CH₂)_dCO₂R^{20'}, CONHN^{21'}R^{22'}, CONR^{13'}SO₂R^{23'}, CO₂R^{24'}, cyano, trifluoromethyl, NR^{8'}R^{9'}, NR^{8'}COR^{10'}, NR^{25'}CO(CH₂)_dNR^{25'}R^{26'}, NR^{25'}CONR^{25'}R^{26'}, NR^{8'}CO₂R^{11'}, NR^{8'}SO₂R^{12'}, N=CNR^{25'}NR^{25'}R^{26'}, nitro, hydroxy, C₁₋₆alkoxy, hydroxyC₁₋₆alkoxy, C₁₋₆alkoxyC₁₋₆alkoxy, OC(O)NR^{27'}R^{28'}, SR^{29'}, SOR^{30'}, SO₂R^{30'}, SO₂NR^{31'}R^{32'}, halogen, C₁₋₆alkanoyl, CO₂(CH₂)_dOR^{33'}, or R^{1'} is an optionally substituted 5 to 7-membered heterocyclic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur;

R^{3'} and R^{5'} are independently hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, hydroxyC₁₋₆alkyl, C₁₋₆alkylOC₁₋₆alkyl, CONR^{34'}R^{35'}, CO₂R^{36'}, cyano, aryl, trifluoromethyl, NR^{37'}R^{38'}, nitro, hydroxy, C₁₋₆alkoxy, C₁₋₆alkanoyl, acyloxy, or halogen;

R^{16'}, R^{17'}, R^{18'}, R^{19'}, R^{20'}, R^{21'}, R^{22'}, R^{25'}, R^{26'}, R^{29'}, R^{33'}, R^{34'}, R^{35'}, R^{36'}, R^{37'}, and R^{38'} are independently hydrogen or C₁₋₆alkyl;

R^{6'} is hydrogen or C₁₋₆alkyl, providing that D is nitrogen or a CH group;

R^{7'} is hydrogen or C₁₋₆alkyl, providing that D is nitrogen or a CH group;

R^{8'} and R^{9'} are independently hydrogen or C₁₋₆alkyl, or R^{8'} and R^{9'} together with the nitrogen to which they are attached, forms a 5- to 6-membered heterocyclic ring, which may optionally be substituted by an oxo group, and, when there are six members, may optionally contain in the ring one oxygen or one sulfur atom;

R^{10'} is hydrogen, C₁₋₆alkyl, or C₁₋₄alkoxyalkyl;

R^{11'}, R^{23'}, and R^{30'} are independently C₁₋₆alkyl;

R^{12'} is C₁₋₆alkyl or phenyl;

R^{13'} and R^{14'} are independently hydrogen or C₁₋₆alkyl, or R^{13'} and R^{14'} together with the nitrogen to which they are attached form a 5- to 6-membered saturated heterocyclic ring which, when there are 6 ring members, may optionally contain in the ring one oxygen or one sulfur atom;

R^{15'} is C₁₋₄alkyl, optionally substituted by C₁₋₆alkoxy;

R^{24'} is hydrogen or C₁₋₆alkyl optionally substituted with one or two substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, hydroxy, or NR^{8'}R^{9'};

$R^{27'}$ and $R^{28'}$ are independently hydrogen or C_{1-6} alkyl, or $R^{27'}$ and $R^{28'}$ together with the nitrogen to which they are attached form a 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or sulfur atom;

$R^{31'}$ and $R^{32'}$ are independently hydrogen or C_{1-6} alkyl, or $R^{31'}$ and $R^{32'}$ together with the nitrogen to which they are attached form 5- to 6-membered heterocyclic ring which, when there are six ring members, may optionally contain in the ring one oxygen or one sulfur atom:

a' and b' are independently 1, 2, or 3;


c' is 0, 1, or 2;

d' is 1, 2, 3, or 4;

e' is 0, 1, 2, or 3;

f' is 1, 2, or 3;

E represents (a):



in which

B is oxygen, $S(O)_c$, $CR^7=CR^8$, or CR^7R^8 , or B is NR^9 ;

R^1 and R^2 are independently hydrogen or C_{1-6} alkyl; alternatively $B(CR^1R^2)_a$ is $OCR^1R^2CR^1(OH)CR^1R^2$ or $OCR^1R^2CR^1(OCOCH_3)CR^1R^2$;

R^3 and R^4 are independently hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where optional substituents include C_{1-6} alkyl, aryl, $CONR^{10}R^{11}$, $NR^{10}R^{11}$, hydroxy, $OCOR^{12}$, $NHCOC_{0-6}$ alkyl where alkyl is optionally substituted by OH, $NHCOCF_3$, $NHSO_2R^{13}$, and $NHCO_2R^{14}$;

R^5 is hydrogen, C_{1-6} alkyl, aryl, CN, $CONR^{15}R^{16}$, CO_2R^{17} , trifluoromethyl, $NHCO_2R^{18}$, hydroxy, C_{1-6} alkoxy, benzyloxy, $OCH_2CO_2C_{1-6}$ alkyl, OCF_3 , $S(O)_dR^{19}$, $SO_2NR^{20}R^{21}$ or halogen;

R^6 is hydrogen, C_{1-6} alkyl, aryl, trifluoromethyl, hydroxy, C_{1-6} alkoxy or halogen, or R^6 taken together with $R^{6'}$ forms a group D where D is $(CR^{22}R^{23})_e$ or D is $(CR^{22}R^{23})_f-G$ where G is oxygen, sulfur or $CR^{22}=CR^{23}$, $CR^{22}=N$, $=CR^{22}O$, $=CR^{22}S$, or $=CR^{22}-NR^{23}$;

R⁷, R⁸, R¹⁰, R¹¹, R¹², R¹⁵, R¹⁶, R¹⁷, R²⁰, R²¹, R²², and R²³ are independently hydrogen or C₁₋₆alkyl;

R⁹ is hydrogen, C₁₋₆alkyl, or phenylC₁₋₆alkyl;

R¹³, R¹⁴, R¹⁸, and R¹⁹ are independently C₁₋₆alkyl;

a is 1, 2, 3, or 4;


b is 1 or 2;

c and d are independently 0, 1 or 2;

e is 2, 3 or 4;

f is 0, 1, 2 or 3;

alternatively, E represents (b):



R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³¹, and R³² are independently hydrogen or C₁₋₆alkyl;

R³⁰ is hydrogen, C₁₋₆alkyl, or C₃₋₇cycloalkyl;

R³³ is hydrogen, C₁₋₆alkyl, trifluoromethyl, hydroxy, or halogen, or

R³³ and R^{6'} together form a group -K- where K is (CR³⁴R³⁵)_i or K is (CR³⁴R³⁵)_j-M and M is oxygen, sulfur, CR³⁴=CR³⁵, CR³⁴=N, or N=N;

J is oxygen, CR³⁶R³⁷, or NR³⁸, or J is a group S(O)_k

R³⁴, R³⁵, R³⁶, R³⁷, and R³⁸ are independently hydrogen or C₁₋₆alkyl;

g is 1, 2 or 3;


h is 1, 2 or 3;

i is 2, 3, or 4;

j is 0, 1, 2, or 3;

k is 0, 1 or 2;

alternatively, E represents (c):




in which:


Q is oxygen, S(O)_n, CR⁴⁴=CR⁴⁵, CR⁴⁴R⁴⁵, or Q is NR⁴⁶;

R³⁹ and R⁴⁰ are independently hydrogen or C₁₋₆alkyl;

R⁴¹ is a group of formula (d):



or R⁴¹ is a group of formula (e):



R⁴² is hydrogen, C₁₋₆alkyl, aryl, CN, CONR⁴⁸R⁴⁹, CO₂R⁵⁰, trifluoromethyl, NHCO₂R⁵¹, hydroxy, C₁₋₆alkoxy, benzyloxy, OCH₂CO₂C₁₋₆alkyl, OCF₃, S(O)₂R⁵², SO₂NR⁵³R⁵⁴, or halogen;

R⁴³ is hydrogen or R⁴³ together with R^{6'} forms a group R where R is CR⁵⁵=CR⁵⁶, CR⁵⁵=CR⁵⁶CR⁵⁵R⁵⁶, or (CR⁵⁵R⁵⁶)_t;

R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁸, R⁴⁹, R⁵⁰, R⁵³, R⁵⁴, R⁵⁵, and R⁵⁶ are independently hydrogen or C₁₋₆alkyl;

R⁴⁷ is hydrogen, C₁₋₆alkyl, or C₃₋₇ cycloalkyl;

R⁵¹ and R⁵² are independently C₁₋₆alkyl;

l is 0, 1, 2, or 3;

m is 1 or 2;

n is 0, 1, or 2


o, p, and q are independently integers having the value 1, 2, or 3;

r is 0, 1, 2, or 3;

s is 0, 1, or 2;

t is 2 or 3;

alternatively, E represents (f):



R⁵⁷ and R⁵⁸ are independently hydrogen or C₁₋₆alkyl;

R⁵⁹ and R⁶⁰ are independently hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5- to 7-membered heterocyclic ring which may contain an additional heteroatom selected from oxygen, nitrogen or sulfur, where

optional substituents include C_{1-6} alkyl, aryl, $CONR^{61}R^{62}$, $NR^{61}R^{62}$, hydroxy, $OCOR^{63}$, $NHCOC_{0-6}$ alkyl where alkyl is optionally substituted by OH, $NHCOCF_3$, $NHSO_2R^{64}$, and $NHCO_2R^{65}$;

T is $-(CR^{66}R^{67})_v-$ or $-O(CR^{66}R^{67})_w-$;

W is oxygen, $S(O)_x$, NR^{68} , or W is $CR^{69}=CR^{70}$ or $CR^{69}R^{70}$;

R^{61} , R^{62} , R^{63} , R^{66} , R^{67} , R^{68} , R^{69} , and R^{70} are independently

hydrogen or C_{1-6} alkyl;

R^{64} and R^{65} are independently C_{1-6} alkyl;


u is 1 to 4;

v is 2 or 3;

w is 1, 2, or 3;

x is 0, 1 or 2;

alternatively, E represents a group (g):



R^{71} is an optionally substituted 5 to 7-membered saturated or partially saturated heterocyclic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur or R^{71} is an optionally substituted 6,6 or 6,5 bicyclic ring containing a nitrogen atom and optionally a further heteroatom selected from oxygen, nitrogen or sulfur;

R^{72} is hydrogen, C_{1-6} alkyl, aryl, CN, $CONR^{74}R^{75}$, CO_2R^{76} , trifluoromethyl, $NHCO_2R^{77}$, hydroxy, C_{1-6} alkoxy, benzyloxy, $OCH_2CO_2C_{1-6}$ alkyl, OCF_3 , $S(O)_2R^{78}$, $SO_2NR^{79}R^{80}$, or halogen;

R^{73} is hydrogen, C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy or halogen, or R^{73} and $R^{6'}$ taken together from a group -X- where X is $(CR^{81}R^{82})_{aa}$ or X is $(CR^{81}R^{82})_{ab}-Y$ and Y is oxygen, sulfur or $CR^{81}=CR^{82}$;

R^{74} , R^{75} , R^{76} , R^{79} , R^{80} , R^{81} , and R^{82} are independently hydrogen or C_{1-6} alkyl;

R^{77} and R^{78} are independently C_{1-6} alkyl;

y is 1 or 2;

z is 0, 1, or 2;


aa is 2, 3 or 4;

ab is 0, 1, 2 or 3;

alternatively, E represents group (h):

ak is 0, 1 or 2.

2. The method of claim 1 wherein the compound of formula (I) is selected from a subgenus of formula (Ia) or formula (Ib) or a pharmaceutically acceptable salt thereof:



wherein R^1 , R^2 , R^3 , R^4 , R^5 , P^1 , P^2 , P^3 , a , b , c , L , R^{24} , R^{25} , R^{26} , R^{27} , R^{28} , R^{29} , R^{30} , R^{31} , R^{32} , R^{33} , J , g , and h are defined in claim 1.

3. The method as claimed in claim 1 wherein the compound is selected from:

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-5-(4-pyridinyl)-2-furancarboxamide;

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-5-(4-pyridyl)-thiophene-2-carboxamide;

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-5-(4-pyridinyl)-3-furancarboxamide;

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-3-methyl-4-(3-thienyl)-benzamide dioxalate;

4-Methoxy-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-5-(4-pyridinyl)-3-thiophenecarboxamide;

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(2-thienyl)-3-methylbenzamide oxalate;

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(4-phenyl-2-thiazolyl)benzamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-(1-pyrrolyl)pyridin-3-carboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-thiophenecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide;

6-Chloro-N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide;

5-Bromo-N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-pyridinecarboxamide;
N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-thiophenecarboxamide;
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(3-pyridinyl)benzamide;
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-pyridinyl)benzamide;
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thiazolyl)-benzamide;
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-phenyl-3-pyridinecarboxamide;
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(4-pyridinyl)benzamide;
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-phenyl-2-pyridinecarboxamide;
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-(2-thienyl)benzamide;
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thienyl)benzamide;
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-phenyl-2-thiophenecarboxamide;
N-[1'-Isopropyl-spiro[benzofuran-3(2H),4'-piperidin]-5-yl]-2-(2,3-dihydro-1,4-benzodioxan-2-yl)-4-thiazolecarboxamide
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;
N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;
N-[3-[2-(Dimethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;
(+)-N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

(-)-N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(3-bromo-2-thienyl)-4-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(3-bromo-2-thienyl)-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-(3-bromo-2-thienyl)-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-methyl-5-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-methyl-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-methyl-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-phenyl-4-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-phenyl-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-phenyl-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-phenyl-5-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-phenyl-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-4-methyl-2-(4-chlorophenyl)-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(4-chlorophenyl)-5-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(4-chlorophenyl)-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-[2-chloro-4-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dichlorophenyl)-4-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-(2,3-dichlorophenyl)-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-(2,3-dichlorophenyl)-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]phenyl]-2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-2-[3-(trifluoromethyl)phenyl]-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-pyrazinyl-5-thiazolecarboxamide;

N-[3-[2-(Diethylamino)ethoxy]-4-methoxyphenyl]-4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-methyl-2-(4-chlorophenyl)-5-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-3-chloro-benzo[b]thiophene-2-carboxamide;

N-[3-[3-[Bis(1-methylethyl)amino]propyl]-4-methoxyphenyl]-3-chloro-benzo[b]thiophene-2-carboxamide;

N-[3-[3-[Bis(1-methylethyl)amino]propoxy]-4-methoxyphenyl]-3-chloro-benzo[b]thiophene-2-carboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide;

N-[3-[3-[Bis(1-methylethyl)amino]propyl]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide;

N-[3-[3-[Bis(1-methylethyl)amino]propoxy]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-1H-indole-2-carboxamide; and

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-2-benzofurancarboxamide,
or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 wherein the CCR5-mediated disease state is selected from COPD, asthma and atopic disorders, rheumatoid arthritis, atherosclerosis, sarcoidosis and other fibrotic disease, psoriasis, autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, and HIV.

5. A compound of formula (I) selected from:

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(2-thienyl)benzamide;

N-[3-[2-(Diisopropylamino)ethoxy]-4-methoxyphenyl]-5-phenyl-2-thiophenecarboxamide;

N-[1'-Isopropyl-spiro[benzofuran-3(2H),4'-piperidin]-5-yl]-2-(2,3-dihydro-1,4-benzodioxan-2-yl)-4-thiazolecarboxamide

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

(+)-N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

(-)-N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4-thiazolecarboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide;

N-[3-[3-[Bis(1-methylethyl)amino]propoxy]-4-methoxyphenyl]-6-chloro-2H-1-benzopyran-3-carboxamide;

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-1H-indole-2-carboxamide; and

N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-chloro-2-benzofurancarboxamide,
or a pharmaceutically acceptable salt thereof.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A01N 43/60, 37/18, 35/00, 43/02, 43/18, 43/12, 43/16, 43/60		A3	(11) International Publication Number: WO 00/06085
			(43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/US99/17118		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 28 July 1999 (28.07.99)			
(30) Priority Data: 60/094,424 28 July 1998 (28.07.98) US 60/094,414 28 July 1998 (28.07.98) US		Published With international search report.	
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US).		(88) Date of publication of the international search report: 4 May 2000 (04.05.00)	
(72) Inventors; and (75) Inventors/Applicants (for US only): NEEB, Michael, J. [US/US]; 414 Bill Smith Boulevard, King of Prussia, PA 19406 (US). BONDINELL, William, E. [US/US]; 1512 Franklin Lane, Wayne, PA 19087 (US). KU, Thomas, W. [US/US]; 1413 Southwind Way, Dresher, PA 19025 (US).			
(74) Agents: STEIN-FERNANDEZ, Nora et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).			
(54) Title: COMPOUNDS AND METHODS			
(57) Abstract This invention relates to substituted heteroanilide compounds which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LJ	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17118

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 43/60, 37/18, 35/00, 43/02, 43/18, 43/12, 43/16, 43/60
US CL : 514/255, 599, 678, 679, 680, 688, 431, 432, 443, 450, 453, 462

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/255, 599, 678, 679, 680, 688, 431, 432, 443, 450, 453, 462

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN: COMPOUNDS AND METHODS OF USE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,000,143 A (DYKSTRA ET AL) 28 December 1976, see entire document.	1-5
A	WO 95/04729 A1 (SMITHKLINE BEECHAM PLC) 16 February 1995, see entire document.	1-5
A	WO 95/06644 A1 (SMITHKLINE BEECHAM PLC) 09 March 1995, see entire document.	1-5
A	WO 95/006637 A1 (SMITHKLINE BEECHAM PLC) 09 March 1995, see entire document.	1-5

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 NOVEMBER 1999

Date of mailing of the international search report

23 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RUSSELL TRAVERS

Telephone No. (703) 308-1235